557795-19-4 | N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide

Packsize	Purity	Availability	Price	Discounted Price
100mg	98%	in stock	$10.00	$7.00
250mg	98%	in stock	$14.00	$10.00
1g	98%	in stock	$33.00	$23.00
5g	98%	in stock	$126.00	$88.00
25g	98%	in stock	$511.00	$358.00

Description

• Catalog Number: AB47424
• Chemical Name: N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide
• CAS Number: 557795-19-4
• Molecular Formula: C22H27FN4O2
• Molecular Weight: 398.4738
• MDL Number: MFCD09260778
• SMILES: CCN(CCNC(=O)c1c(C)[nH]c(c1C)/C=C/1\C(=O)Nc2c1cc(F)cc2)CC
• NSC Number: 750690

Computed Properties

• Complexity: 636
• Covalently-Bonded Unit Count: 1
• Defined Bond Stereocenter Count: 1
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 7
• XLogP3: 2.6

Literature

• Sunitinib induces hepatocyte mitochondrial damage and apoptosis in mice.

  Toxicology 20181101

• Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.

  Toxicology letters 20180701

• Human precision-cut liver slices as a model to test antifibrotic drugs in the early onset of liver fibrosis.

  Toxicology in vitro : an international journal published in association with BIBRA 20160901

• Differential Effects of Sunitinib on the Expression Profiles of Xenobiotic-Metabolizing Enzymes and Transporters in Rat Liver and Kidneys.

  Basic & clinical pharmacology & toxicology 20160801

• Inflammatory and fibrotic processes are involved in the cardiotoxic effect of sunitinib: Protective role of L-carnitine.

  Toxicology letters 20160122

• Identification of a Mitochondrial DNA Polymerase Affecting Cardiotoxicity of Sunitinib Using a Genome-Wide Screening on S. pombe Deletion Library.

  Toxicological sciences : an official journal of the Society of Toxicology 20160101

• Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.

  Toxicological sciences : an official journal of the Society of Toxicology 20151101

• Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.

  Toxicological sciences : an official journal of the Society of Toxicology 20150601

• Suppression of cancer relapse and metastasis by inhibiting cancer stemness.

  Proceedings of the National Academy of Sciences of the United States of America 20150210

• Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.

  European journal of clinical pharmacology 20150101

• Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.

  Journal of medicinal chemistry 20141009

• Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries.

  Chemico-biological interactions 20140625

• Development of cardiac hypertrophy by sunitinib in vivo and in vitro rat cardiomyocytes is influenced by the aryl hydrocarbon receptor signaling pathway.

  Archives of toxicology 20140301

• Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs.

  Toxicology and applied pharmacology 20140115

• A high-throughput screen for teratogens using human pluripotent stem cells.

  Toxicological sciences : an official journal of the Society of Toxicology 20140101

• Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.

  Cancer science 20140101

• Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.

  Toxicological sciences : an official journal of the Society of Toxicology 20131201

• Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.

  Toxicology and applied pharmacology 20131001

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• The development of CNS-active LRRK2 inhibitors using property-directed optimisation.

  Bioorganic & medicinal chemistry letters 20130701

• Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation.

  Archives of toxicology 20130501

• Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20130501

• A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

  The Biochemical journal 20130415

• Activity-based kinase profiling of approved tyrosine kinase inhibitors.

  Genes to cells : devoted to molecular & cellular mechanisms 20130201

• A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology.

  PloS one 20130101

• A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.

  Journal of drug targeting 20121201

• Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.

  Bioorganic & medicinal chemistry letters 20121201

• A pilot study of sunitinib malate in patients with metastatic uveal melanoma.

  Melanoma research 20121201

• Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.

  Biomedical chromatography : BMC 20121101

• Sunitinib causes dose-dependent negative functional effects on myocardium and cardiomyocytes.

  BJU international 20121101

• Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC).

  BJU international 20121101

• An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.

  European journal of cancer (Oxford, England : 1990) 20121101

• Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker.

  Journal of pharmaceutical and biomedical analysis 20121101

• Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.

  The Journal of pharmacology and experimental therapeutics 20121101

• Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.

  Neuro-oncology 20121101

• Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20121101

• Lung toxicity in a patient treated with sunitinib.

  The European respiratory journal 20121101

• Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-γ-related pathways.

  American journal of physiology. Endocrinology and metabolism 20121015

• Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer.

  British journal of cancer 20121009

• Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma.

  American journal of clinical oncology 20121001

• Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function.

  Cardiovascular therapeutics 20121001

• Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?

  International journal of urology : official journal of the Japanese Urological Association 20121001

• C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib.

  International journal of urology : official journal of the Japanese Urological Association 20121001

• Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20121001

• Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence?

  Cancer biotherapy & radiopharmaceuticals 20121001

• Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells.

  Molecular oncology 20121001

• Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors.

  The Journal of surgical research 20121001

• A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma.

  Journal of neuro-oncology 20121001

• Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.

  The Journal of clinical endocrinology and metabolism 20121001

• Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20121001

• Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.

  Clinical pharmacology and therapeutics 20121001

• Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.

  The Annals of pharmacotherapy 20121001

• Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.

  Urologic oncology 20120901

• The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.

  Urologic oncology 20120901

• Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.

  European journal of radiology 20120901

• Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?

  Medical oncology (Northwood, London, England) 20120901

• Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib.

  Journal of cellular and molecular medicine 20120901

• A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120901

• Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.

  BJU international 20120901

• A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120901

• Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model.

  Urology 20120901

• Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.

  The Journal of clinical endocrinology and metabolism 20120901

• Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120901

• A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120901

• [Partial nephrectomy after neoadjuvant administration of sunitinib facilitates preservation of a solitary kidney].

  Aktuelle Urologie 20120901

• Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.

  Targeted oncology 20120901

• Rapid relapse after resection of a sunitinib-resistant gastrointestinal stromal tumor harboring a secondary mutation in exon 13 of the c-KIT gene.

  Anticancer research 20120901

• [Responses to treatment and switching tyrosine kinase inhibitors in gastrointestinal stromal tumor(GIST)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120901

• [A case of interstitial lung disease due to sunitinib].

  Hinyokika kiyo. Acta urologica Japonica 20120901

• [Cardiac tamponade due to pericardial metastasis from renal cell carcinoma : a case report].

  Hinyokika kiyo. Acta urologica Japonica 20120901

• Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer.

  Cancer letters 20120828

• Takotsubo syndrome in a patient treated with sunitinib for renal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120820

• Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer.

  International journal of cancer 20120815

• Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.

  Investigational new drugs 20120801

• Docetaxel combined with targeted therapies in metastatic breast cancer.

  Cancer treatment reviews 20120801

• Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma.

  International journal of clinical oncology 20120801

• Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.

  Cancer treatment reviews 20120801

• VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.

  Annals of surgical oncology 20120801

• Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120801

• Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.

  Breast (Edinburgh, Scotland) 20120801

• Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model.

  The Journal of pathology 20120801

• Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells.

  European journal of cancer (Oxford, England : 1990) 20120801

• Reproductive toxicity assessment of sunitinib, a multitargeted receptor tyrosine kinase inhibitor, in male and female rats.

  Birth defects research. Part B, Developmental and reproductive toxicology 20120801

• First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.

  Cancer science 20120801

• Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20120801

• A case of acute adrenal insufficiency unmasked during sunitinib treatment for metastatic renal cell carcinoma.

  Japanese journal of clinical oncology 20120801

• Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.

  The Journal of pathology 20120801

• Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.

  The Journal of pathology 20120801

• Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.

  Japanese journal of clinical oncology 20120801

• Effect of sunitinib on functional reproductive outcome in a rabbit model.

  Fertility and sterility 20120801

• The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.

  Bioorganic & medicinal chemistry letters 20120801

• FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.

  The oncologist 20120801

• Targeting angiogenesis in metastatic breast cancer.

  The oncologist 20120801

• Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer.

  Journal of chemotherapy (Florence, Italy) 20120801

• PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.

  International journal of cancer 20120715

• The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.

  Biochemical pharmacology 20120715

• Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120715

• Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.

  Bioorganic & medicinal chemistry 20120715

• A biodegradable perivascular wrap for controlled, local and directed drug delivery.

  Journal of controlled release : official journal of the Controlled Release Society 20120710

• Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome.

  American journal of therapeutics 20120701

• Lung Aspergillosis in renal cell carcinoma patient treated with sunitinib.

  QJM : monthly journal of the Association of Physicians 20120701

• Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion.

  Journal of cellular and molecular medicine 20120701

• Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model.

  Breast cancer research and treatment 20120701

• HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.

  Cancer letters 20120701

• Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120701

• High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.

  Current cancer drug targets 20120701

• Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells.

  Molecular cancer therapeutics 20120701

• 2-Anilino-4-(benzimidazol-2-yl)pyrimidines--a multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines.

  European journal of medicinal chemistry 20120701

• Adjuvant therapy of gastrointestinal stromal tumors.

  Current opinion in oncology 20120701

• In vivo, in vitro toxicity and in vitro angiogenic inhibition of sunitinib malate.

  Current eye research 20120701

• Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120701

• A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20120701

• Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120701

• Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma.

  Anticancer research 20120701

• Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.

  European review for medical and pharmacological sciences 20120701

• [A case of advanced renal cell carcinoma with inferior vena cava thrombus treated with sunitinib as neoadjuvant therapy].

  Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20120701

• Sunitinib-induced hyperparathyroidism: a possible mechanism to altered bone homeostasis.

  Cancer 20120615

• Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120610

• Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.

  Medical oncology (Northwood, London, England) 20120601

• Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.

  Medical oncology (Northwood, London, England) 20120601

• Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.

  Medical oncology (Northwood, London, England) 20120601

• Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.

  International journal of cancer 20120601

• Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose.

  Journal of gastrointestinal cancer 20120601

• Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120601

• A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120601

• Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease.

  Arthritis and rheumatism 20120601

• Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.

  Clinical genitourinary cancer 20120601

• Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.

  Clinical and experimental nephrology 20120601

• Is apparent diffusion coefficient reliable and accurate for monitoring effects of antiangiogenic treatment in a longitudinal study?

  Journal of magnetic resonance imaging : JMRI 20120601

• Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.

  Journal of cancer research and clinical oncology 20120601

• Current treatment considerations in metastatic renal cell carcinoma.

  Current treatment options in oncology 20120601

• Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?

  Current oncology reports 20120601

• Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.

  The Journal of clinical endocrinology and metabolism 20120601

• Underestimating cardiac toxicity in cancer trials: lessons learned?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120601

• Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.

  Molecular diagnosis & therapy 20120601

• Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience.

  Asia-Pacific journal of clinical oncology 20120601

• Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.

  Targeted oncology 20120601

• New targeted agents in gastroenteropancreatic neuroendocrine tumors.

  Targeted oncology 20120601

• Sunitinib malate for the treatment of renal cell carcinoma.

  Expert opinion on pharmacotherapy 20120601

• Sunitinib in pancreatic neuroendocrine tumors.

  Targeted oncology 20120601

• Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120601

• Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma.

  Chinese medical journal 20120601

• [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].

  Zhonghua bing li xue za zhi = Chinese journal of pathology 20120601

• Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.

  British journal of cancer 20120508

• Novel molecular targeted therapies for refractory thyroid cancer.

  Head & neck 20120501

• Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.

  BJU international 20120501

• Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.

  Annals of surgical oncology 20120501

• Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.

  European journal of gastroenterology & hepatology 20120501

• Cancer therapy modulates VEGF signaling and viability in adult rat cardiac microvascular endothelial cells and cardiomyocytes.

  Journal of molecular and cellular cardiology 20120501

• Evaluation of subchronic toxicity of SIM010603, a potent inhibitor of receptor tyrosine kinase, after 28-day repeated oral administration in SD rats and beagle dogs.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20120501

• Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.

  International journal of oncology 20120501

• Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.

  European journal of cancer (Oxford, England : 1990) 20120501

• Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.

  European journal of cancer (Oxford, England : 1990) 20120501

• The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery.

  The Journal of urology 20120501

• Synthesis and evaluation of 2-[2-(phenylthiomethyl)-1H-benzo[d] imidazol-1-yl)acetohydrazide derivatives as antitumor agents.

  Bioorganic & medicinal chemistry letters 20120501

• Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice.

  The Journal of clinical investigation 20120501

• Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis.

  Recent patents on endocrine, metabolic & immune drug discovery 20120501

• Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus.

  Anticancer research 20120501

• Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib--a case report.

  Anticancer research 20120501

• [Metastatic apocrine adenocarcinoma of the penis: cytostatic therapy].

  Aktuelle Urologie 20120501

• Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.

  Future oncology (London, England) 20120501

• Sunitinib and pancreatic neuroendocrine tumours. More assessment needed.

  Prescrire international 20120501

• Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.

  Journal of medicinal chemistry 20120426

• Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.

  British journal of cancer 20120424

• Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120420

• Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.

  International journal of cancer 20120415

• Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120415

• Radioiodinated sunitinib as a potential radiotracer for imaging angiogenesis-radiosynthesis and first radiopharmacological evaluation of 5-[125I]Iodo-sunitinib.

  Bioorganic & medicinal chemistry letters 20120415

• Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.

  Investigational new drugs 20120401

• Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.

  Investigational new drugs 20120401

• A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.

  Investigational new drugs 20120401

• Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.

  Cancer 20120401

• Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street?

  Cancer 20120401

• Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.

  Cancer 20120401

• Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction.

  Clinical and experimental nephrology 20120401

• Sporadic CNS hemangioblastomatosis, response to sunitinib and secondary polycythemia.

  Journal of neuro-oncology 20120401

• Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.

  Cancer chemotherapy and pharmacology 20120401

• Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study.

  Cancer chemotherapy and pharmacology 20120401

• Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.

  Journal of cancer research and clinical oncology 20120401

• P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.

  The Journal of pharmacology and experimental therapeutics 20120401

• Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma.

  Japanese journal of clinical oncology 20120401

• New strategies for advanced neuroendocrine tumors in the era of targeted therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120401

• Intracranial metastasis from pediatric GI stromal tumor.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120401

• Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120401

• Cutaneous side effects associated with sunitinib: an analysis of 8 cases.

  International journal of clinical pharmacy 20120401

• The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma.

  Neurological research 20120401

• Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.

  The Kaohsiung journal of medical sciences 20120401

• Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome.

  Archives of dermatology 20120401

• First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120320

• Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD.

  American journal of physiology. Endocrinology and metabolism 20120315

• Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120310

• Three cases of severe ulcerative esophagitis induced by SUTENT®.

  Journal of gastrointestinal cancer 20120301

• Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?

  Annals of oncology : official journal of the European Society for Medical Oncology 20120301

• Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120301

• Determining the optimal dose and schedule of sunitinib: some answers, more questions.

  Cancer 20120301

• Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

  Cancer 20120301

• A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20120301

• RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.

  Gynecologic oncology 20120301

• [Renal tolerance of targeted therapies].

  Bulletin du cancer 20120301

• Small intestine gastrointestinal stromal tumors.

  Current opinion in gastroenterology 20120301

• Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.

  Drug metabolism and disposition: the biological fate of chemicals 20120301

• Alveolar soft part sarcoma in childhood: is Sunitinib-Sutent® treatment an effective approach?

  Pediatric blood & cancer 20120301

• Sunitinib therapy for melanoma patients with KIT mutations.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120301

• Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma.

  Advances in therapy 20120301

• Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.

  Anticancer research 20120301

• [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].

  Magyar onkologia 20120301

• [Resistance and treatment strategy of gastrointestinal stromal tumor target therapy].

  Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20120301

• Drug-induced palate osteonecrosis following nasal surgery.

  The Israel Medical Association journal : IMAJ 20120301

• Sunitinib related osteonecrosis of jaw: a case report.

  Oral surgery, oral medicine, oral pathology and oral radiology 20120301

• Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis.

  British journal of cancer 20120227

• Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene.

  International journal of cancer 20120215

• Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.

  International journal of cancer 20120215

• Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.

  Cancer 20120215

• Angiogenesis inhibitors identified by cell-based high-throughput screening: synthesis, structure-activity relationships and biological evaluation of 3-[(E)-styryl]benzamides that specifically inhibit endothelial cell proliferation.

  Bioorganic & medicinal chemistry 20120215

• Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.

  British journal of cancer 20120214

• Second-line treatment for renal cell cancer.

  British journal of cancer 20120214

• Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210

• Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210

• Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.

  Investigational new drugs 20120201

• Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.

  International journal of cancer 20120201

• Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120201

• [KIT and KIT: from biology to clinical use].

  Bulletin du cancer 20120201

• Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery.

  Urology 20120201

• Recurrent anaplastic meningioma treated by sunitinib based on results from quantitative proteomics.

  Neuropathology and applied neurobiology 20120201

• Anti-angiogenic therapy: concept to clinic.

  Microcirculation (New York, N.Y. : 1994) 20120201

• Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells.

  Thyroid : official journal of the American Thyroid Association 20120201

• Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib.

  International journal of dermatology 20120201

• Inhibition of neuroblastoma cell proliferation with omega-3 fatty acids and treatment of a murine model of human neuroblastoma using a diet enriched with omega-3 fatty acids in combination with sunitinib.

  Pediatric research 20120201

• Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.

  Anticancer research 20120201

• Complete pathological response after sequential therapy with sunitinib and radiotherapy for metastatic clear cell renal carcinoma.

  Anticancer research 20120201

• [Urgent patient admission to Working Group for Urological Oncology (AUO) studies on metastasized renal cell carcinoma needed: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma ± adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 of the AUO)].

  Der Urologe. Ausg. A 20120201

• Efficacy of Tie2 receptor antagonism in angiosarcoma.

  Neoplasia (New York, N.Y.) 20120201

• Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications.

  Oral surgery, oral medicine, oral pathology and oral radiology 20120201

• Structural and functional analysis of KIT gene encoding receptor tyrosine kinase and its interaction with sunitinib and HDAC inhibitors: an in silico approach.

  Pakistan journal of biological sciences : PJBS 20120201

• VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.

  Journal of medicinal chemistry 20120126

• Targeted therapies for renal cell carcinoma: review of adverse event management strategies.

  Journal of the National Cancer Institute 20120118

• Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.

  Cancer cell 20120117

• N⁴-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors.

  Bioorganic & medicinal chemistry 20120115

• An update on targeted therapy in metastatic renal cell carcinoma.

  Urologic oncology 20120101

• Treatment of multidrug resistant advanced alveolar soft part sarcoma with sunitinib.

  American journal of therapeutics 20120101

• Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer.

  Urologic oncology 20120101

• Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.

  International journal of cancer 20120101

• A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120101

• Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines.

  Kidney & blood pressure research 20120101

• Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.

  Journal of biochemistry 20120101

• Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.

  Hepatology (Baltimore, Md.) 20120101

• Tyrosine kinase inhibitor sunitinib relieves systemic and oral antigen-induced anaphylaxes in mice.

  Allergy 20120101

• The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.

  European journal of cancer (Oxford, England : 1990) 20120101

• Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport.

  The Journal of clinical endocrinology and metabolism 20120101

• Gastrointestinal stromal tumors of the stomach.

  Surgical oncology clinics of North America 20120101

• Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress.

  Hypertension (Dallas, Tex. : 1979) 20120101

• A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study.

  European journal of cancer (Oxford, England : 1990) 20120101

• An adaptive group sequential phase II design to compare treatments for survival endpoints in rare patient entities.

  Journal of biopharmaceutical statistics 20120101

• Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells.

  International journal of nanomedicine 20120101

• Steve Jobs's cancer. Pancreatic neuroendocrine tumors are becoming more common (the bad news) and also more treatable (the good news).

  Harvard health letter 20120101

• Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib.

  Chemotherapy 20120101

• The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.

  BMC cancer 20120101

• Sunitinib malate.

  Profiles of drug substances, excipients, and related methodology 20120101

• Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.

  BMC cancer 20120101

• Sunitinib-induced autoimmune thyroiditis in a patient with metastatic renal cell carcinoma: a case report.

  Chemotherapy 20120101

• Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.

  Urologia internationalis 20120101

• Current management of gastrointestinal stromal tumors--a comprehensive review.

  International journal of surgery (London, England) 20120101

• Sunitinib treatment for refractory malignant pheochromocytoma.

  Neuro endocrinology letters 20120101

• A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.

  Oncology 20120101

• Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?

  World journal of surgical oncology 20120101

• Epithelioid hemangioendothelioma of the kidney treated with sunitinib.

  Onkologie 20120101

• Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.

  PloS one 20120101

• Chronic VEGF blockade worsens glomerular injury in the remnant kidney model.

  PloS one 20120101

• Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?

  Chemotherapy 20120101

• Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases.

  PloS one 20120101

• Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.

  Oncology 20120101

• Sunitinib-sensitive suicidal erythrocyte death.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20120101

• Sunitinib and everolimus in pancreatic neuroendocrine tumors.

  Tumori 20120101

• Severe perirenal hematoma in a patient with a single kidney treated with sunitinib for metastatic pancreatic neuroendocrine tumor.

  Journal of cancer research and therapeutics 20120101

• Sunitinib in patients with cisplatin-refractory germ cell tumors.

  Onkologie 20120101

• The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA.

  PloS one 20120101

• Hypothyroidism during treatment with tyrosine kinase inhibitors.

  Endokrynologia Polska 20120101

• Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.

  Current topics in medicinal chemistry 20120101

• Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.

  Journal (Canadian Dental Association) 20120101

• Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.

  Immunological investigations 20120101

• The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells.

  PloS one 20120101

• Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.

  PloS one 20120101

• A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.

  Cancer 20111215

• Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111215

• A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.

  Circulation research 20111209

• Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.

  Journal of the National Cancer Institute 20111207

• Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.

  British journal of cancer 20111206

• Phase II study of sunitinib as second-line treatment for advanced gastric cancer.

  Investigational new drugs 20111201

• Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.

  Investigational new drugs 20111201

• Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.

  Medical oncology (Northwood, London, England) 20111201

• VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption.

  Investigational new drugs 20111201

• Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib.

  Medical oncology (Northwood, London, England) 20111201

• Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma.

  Medical oncology (Northwood, London, England) 20111201

• Sunitinib-induced severe hypothyroidism with cardiac compromise.

  Medical oncology (Northwood, London, England) 20111201

• Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.

  World journal of urology 20111201

• Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT.

  Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20111201

• Management of recurrent gastrointestinal stromal tumors.

  Journal of surgical oncology 20111201

• Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.

  International journal of clinical oncology 20111201

• Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20111201

• Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

  Annals of oncology : official journal of the European Society for Medical Oncology 20111201

• Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20111201

• Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.

  Journal of neuro-oncology 20111201

• Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib.

  European urology 20111201

• Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.

  European urology 20111201

• Heart failure associated with sunitinib: lessons learned from animal models.

  Current hypertension reports 20111201

• Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination.

  Angiogenesis 20111201

• Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity.

  Current hypertension reports 20111201

• Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111201

• Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.

  Japanese journal of clinical oncology 20111201

• Synthesis and biological evaluation of 2-indolinone derivatives as potential antitumor agents.

  European journal of medicinal chemistry 20111201

• Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma.

  International immunopharmacology 20111201

• Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.

  Journal of surgical oncology 20111201

• Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.

  Journal of surgical oncology 20111201

• Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.

  European journal of cancer (Oxford, England : 1990) 20111201

• Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management.

  Targeted oncology 20111201

• Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.

  Annals of oncology : official journal of the European Society for Medical Oncology 20111201

• Sunitinib for advanced pancreatic neuroendocrine tumors.

  Expert review of anticancer therapy 20111201

• Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20111201

• New insights into molecular mechanisms of sunitinib-associated side effects.

  Molecular cancer therapeutics 20111201

• VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.

  Anticancer research 20111201

• Sorafenib: muscle wasting.

  Prescrire international 20111201

• Novel therapies for metastatic castrate-resistant prostate cancer.

  Journal of the National Cancer Institute 20111116

• Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations.

  Toxicology and applied pharmacology 20111115

• Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.

  British journal of cancer 20111108

• Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.

  International journal of cancer 20111101

• Suppressing effects of sunitinib on allergic rhinitis: previously undefined side effects with therapeutic potential.

  Journal of clinical pharmacology 20111101

• A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices.

  Annals of oncology : official journal of the European Society for Medical Oncology 20111101

• Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.

  Cancer 20111101

• Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.

  Expert opinion on pharmacotherapy 20111101

• Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.

  Cancer science 20111101

• Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors.

  Oncology reports 20111101

• Neurosensory retinal detachment due to sunitinib treatment.

  Eye (London, England) 20111101

• Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.

  Clinical endocrinology 20111101

• Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.

  Current cancer drug targets 20111101

• BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells.

  Bioorganic & medicinal chemistry letters 20111101

• Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma.

  Japanese journal of clinical oncology 20111101

• Clinical experience with antiangiogenic therapy in leukemia.

  Current cancer drug targets 20111101

• Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111101

• Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.

  The Lancet. Oncology 20111101

• Targeted therapy for patients with renal-cell carcinoma.

  The Lancet. Oncology 20111101

• Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.

  Nature biotechnology 20111101

• Sunitinib-induced asthenia: from molecular basis to clinical relief.

  Cancer biology & therapy 20111101

• Tyrosine kinase inhibitors for metastatic renal cell carcinoma.

  Drug and therapeutics bulletin 20111101

• [Advanced sarcomatoid renal cell carcinoma effectively treated with sunitinib: report of a case].

  Hinyokika kiyo. Acta urologica Japonica 20111101

• [Twenty-one-year survival case of rectal GIST treated with combined therapies].

  Gan to kagaku ryoho. Cancer & chemotherapy 20111101

• [A case of gastrointestinal stromal tumor (GIST) successfully treated with resection after a long-term control medication by molecular targeted drugs].

  Gan to kagaku ryoho. Cancer & chemotherapy 20111101

• Comprehensive analysis of kinase inhibitor selectivity.

  Nature biotechnology 20111030

• Reversible cardiomyopathy associated with sunitinib and sorafenib.

  The New England journal of medicine 20111027

• Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.

  International journal of cancer 20111015

• Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.

  Cancer 20111015

• Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia.

  Cancer research 20111015

• Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.

  Investigational new drugs 20111001

• Blue toe syndrome and sunitinib.

  International journal of clinical oncology 20111001

• A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib.

  International journal of clinical oncology 20111001

• Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.

  BJU international 20111001

• Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.

  BJU international 20111001

• Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.

  BJU international 20111001

• Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.

  BJU international 20111001

• Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.

  Acta oncologica (Stockholm, Sweden) 20111001

• Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation.

  Journal of leukocyte biology 20111001

• A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.

  Urology 20111001

• Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.

  The Journal of clinical endocrinology and metabolism 20111001

• The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.

  Molecular cancer therapeutics 20111001

• Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.

  Current cancer drug targets 20111001

• Flare up of symptoms after discontinuation of sunitinib in patient with lung cancer.

  Acta oncologica (Stockholm, Sweden) 20111001

• Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.

  European journal of medicinal chemistry 20111001

• Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.

  Endocrine 20111001

• Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20111001

• New target therapies for patients with neuroendocrine tumors of the pancreas.

  Expert review of gastroenterology & hepatology 20111001

• [Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].

  Bulletin du cancer 20111001

• Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors.

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20111001

• Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.

  The Annals of pharmacotherapy 20111001

• Case report of pneumatosis intestinalis secondary to sunitinib treatment for refractory gastrointestinal stromal tumor.

  Anticancer research 20111001

• Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus.

  Anticancer research 20111001

• Gastrointestinal stromal tumor: advances in diagnosis and management.

  Archives of pathology & laboratory medicine 20111001

• Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer.

  Urology 20111001

• [Dermatologic side effects induced by new angiogenesis inhibitors].

  Bulletin du cancer 20111001

• Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.

  Journal of analytical toxicology 20111001

• Reappraising antiangiogenic therapy for breast cancer.

  Breast (Edinburgh, Scotland) 20111001

• HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants.

  PLoS genetics 20111001

• Circulating perivascular progenitors: a target of PDGFR inhibition.

  International journal of cancer 20110915

• Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110915

• Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20110901

• Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20110901

• Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.

  Cancer chemotherapy and pharmacology 20110901

• Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma.

  BJU international 20110901

• Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.

  BJU international 20110901

• Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.

  Leukemia research 20110901

• [Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].

  Der Urologe. Ausg. A 20110901

• Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma.

  Anti-cancer drugs 20110901

• Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination.

  European journal of cancer (Oxford, England : 1990) 20110901

• The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.

  European urology 20110901

• New therapeutic options for metastatic malignant insulinomas.

  Clinical endocrinology 20110901

• Sunitinib prior to planned cytoreductive nephrectomy: is this the new litmus test for metastatic renal cell carcinoma?

  European urology 20110901

• Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.

  Cancer biology & therapy 20110901

• Sunitinib-induced acute psychosis: case report.

  Clinical genitourinary cancer 20110901

• The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110901

• Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.

  Journal of cancer research and clinical oncology 20110901

• Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110901

• VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib.

  Diagnostic molecular pathology : the American journal of surgical pathology, part B 20110901

• Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.

  HPB : the official journal of the International Hepato Pancreato Biliary Association 20110901

• Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110901

• Renal carcinoma with (6;11)(p21;q12) translocation: report of an adult case.

  Pathology international 20110901

• Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.

  Future oncology (London, England) 20110901

• Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.

  Chinese medical journal 20110901

• Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.

  Blood 20110825

• Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110815

• Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.

  Cancer chemotherapy and pharmacology 20110801

• A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST.

  Cancer treatment reviews 20110801

• Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110801

• Added value of molecular targeted agents in oncology.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110801

• Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit.

  Critical reviews in biochemistry and molecular biology 20110801

• Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.

  Radiology 20110801

• Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: a case report.

  Diabetes research and clinical practice 20110801

• Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.

  European journal of cancer (Oxford, England : 1990) 20110801

• Vasculatures in tumors growing from preirradiated tissues: formed by vasculogenesis and resistant to radiation and antiangiogenic therapy.

  International journal of radiation oncology, biology, physics 20110801

• Design, synthesis and biological evaluation of novel 4-thiazolidinones containing indolin-2-one moiety as potential antitumor agent.

  European journal of medicinal chemistry 20110801

• Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response.

  European urology 20110801

• The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system.

  Hypertension (Dallas, Tex. : 1979) 20110801

• Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110801

• The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature.

  Mini reviews in medicinal chemistry 20110801

• Arthrinins A-D: novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp.

  Bioorganic & medicinal chemistry 20110801

• Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.

  Hematology/oncology clinics of North America 20110801

• FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.

  The oncologist 20110801

• Cost-effectiveness of sunitinib in metastatic renal cell carcinoma.

  Expert review of pharmacoeconomics & outcomes research 20110801

• Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model.

  Nuclear medicine and biology 20110801

• Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines.

  The Canadian journal of urology 20110801

• [Gastrointestinal stromal tumour (GIST): current standards in multimodal management].

  Zentralblatt fur Chirurgie 20110801

• [Systemic treatment of renal cell carcinoma - recent update].

  Wiener medizinische Wochenschrift (1946) 20110801

• A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.

  Cancer discovery 20110801

• Inhibition of RNase L and RNA-dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity.

  The Journal of biological chemistry 20110729

• [Adverse effects of new oncologic therapies].

  Praxis 20110727

• Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival.

  Transplantation 20110715

• Phase II study of sunitinib malate in patients with recurrent high-grade glioma.

  Journal of neuro-oncology 20110701

• Myeloid derived suppressor cells in human diseases.

  International immunopharmacology 20110701

• Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110701

• MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

  International immunopharmacology 20110701

• Sunitinib inhibits postoperative adhesions in a rabbit model.

  Surgery 20110701

• Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.

  Current opinion in oncology 20110701

• Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110701

• The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer.

  European journal of cancer (Oxford, England : 1990) 20110701

• An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer.

  European journal of cancer (Oxford, England : 1990) 20110701

• Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.

  Current opinion in oncology 20110701

• An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.

  Expert opinion on pharmacotherapy 20110701

• Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110701

• Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.

  The Lancet. Oncology 20110701

• Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110701

• Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110701

• [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

  Aktuelle Urologie 20110701

• Irreversible Nek2 kinase inhibitors with cellular activity.

  Journal of medicinal chemistry 20110623

• Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110620

• A proof of concept phase II non-inferiority criterion.

  Statistics in medicine 20110615

• Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer.

  Cancer biology & therapy 20110615

• Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population.

  Medical oncology (Northwood, London, England) 20110601

• Tubulocystic renal carcinoma: a clinical perspective.

  World journal of urology 20110601

• Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20110601

• Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients.

  World journal of urology 20110601

• Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110601

• Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability.

  Journal of molecular medicine (Berlin, Germany) 20110601

• Mutational spectrum and therapy response of metastasized GIST in Central Switzerland - a population-based study.

  European journal of cancer (Oxford, England : 1990) 20110601

• Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor.

  Anti-cancer drugs 20110601

• The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus.

  European urology 20110601

• Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?

  Annals of oncology : official journal of the European Society for Medical Oncology 20110601

• MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.

  Cancer immunology, immunotherapy : CII 20110601

• Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice.

  Anti-cancer drugs 20110601

• Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.

  European journal of medicinal chemistry 20110601

• Targeted caval cytoreduction: solid foundations or shifting sands?

  European urology 20110601

• Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.

  World journal of urology 20110601

• The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.

  The Journal of clinical endocrinology and metabolism 20110601

• Treatment of metastatic renal cell carcinoma and renal pelvic cancer.

  Clinical and experimental nephrology 20110601

• [Gottron-like papules induced by sunitinib].

  Actas dermo-sifiliograficas 20110601

• Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.

  Molecular cancer therapeutics 20110601

• Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110601

• [New therapeutic options for advanced thyroid cancer].

  Deutsche medizinische Wochenschrift (1946) 20110601

• Targeting angiogenesis in esophagogastric adenocarcinoma.

  The oncologist 20110601

• [Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110601

• Bevacizumab, sunitinib: osteonecrosis of the jaw.

  Prescrire international 20110601

• Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.

  Clinical therapeutics 20110601

• Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.

  British journal of cancer 20110524

• Synthesis and antitumor activity of 5-[1-(3-(dimethylamino)propyl)-5-halogenated-2-oxoindolin-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamides.

  Bioorganic & medicinal chemistry letters 20110515

• Advances in pancreatic neuroendocrine tumor treatment.

  The New England journal of medicine 20110512

• Advances in pancreatic neuroendocrine tumor treatment.

  The New England journal of medicine 20110512

• Advances in pancreatic neuroendocrine tumor treatment.

  The New England journal of medicine 20110512

• Advances in pancreatic neuroendocrine tumor treatment.

  The New England journal of medicine 20110512

• Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

  Journal of the National Cancer Institute 20110504

• Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals.

  Cancer chemotherapy and pharmacology 20110501

• Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.

  Cancer treatment reviews 20110501

• Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2.

  Journal of cancer research and clinical oncology 20110501

• Sunitinib for the treatment of metastatic renal cell carcinoma.

  Cancer treatment reviews 20110501

• Lower limbs erosions induced by sunitinib.

  Acta dermato-venereologica 20110501

• Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma.

  Journal of hepatology 20110501

• Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.

  Angiogenesis 20110501

• Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma.

  Acta oncologica (Stockholm, Sweden) 20110501

• The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110501

• Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.

  Drug metabolism and disposition: the biological fate of chemicals 20110501

• Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.

  European urology 20110501

• Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors.

  Nature reviews. Clinical oncology 20110501

• Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.

  Leukemia & lymphoma 20110501

• Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.

  Cancer investigation 20110501

• Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy.

  British journal of clinical pharmacology 20110501

• Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.

  The oncologist 20110501

• Novel nephrotoxins.

  Advances in chronic kidney disease 20110501

• [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110501

• [A case of imatinib-resistant GIST treated by sunitinib].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110501

• [Indications and current development of new targeted therapies in pediatric oncology].

  Bulletin du cancer 20110501

• Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110501

• Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.

  World journal of gastroenterology 20110428

• [Novelties in the treatment for advanced renal-cell cancer].

  Orvosi hetilap 20110424

• Recent studies show promise for treating rare pancreatic tumors.

  Journal of the National Cancer Institute 20110420

• IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

• Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.

  Molecular pharmaceutics 20110404

• Metastatic collecting duct carcinoma of the kidney responded to sunitinib.

  International journal of clinical oncology 20110401

• Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110401

• Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110401

• Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.

  Breast (Edinburgh, Scotland) 20110401

• Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.

  European urology 20110401

• Mitotane has a strong and a durable inducing effect on CYP3A4 activity.

  European journal of endocrinology 20110401

• Pyoderma gangrenosum with the use of sunitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110401

• Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma.

  Urology 20110401

• Neoadjuvant systemic therapy or early cystectomy? Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder.

  Urology 20110401

• Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.

  Urology 20110401

• Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110401

• Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.

  The Journal of pathology 20110401

• Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of sunitinib (SU11248) and its active metabolite, N-desethyl sunitinib (SU12662), in human plasma: application to an explorative study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110401

• Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110401

• [Treatment of metastatic renal cell carcinoma].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20110401

• Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.

  Anticancer research 20110401

• Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.

  Clinical breast cancer 20110401

• Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110320

• Translational medicine: Cancer lessons from mice to humans.

  Nature 20110317

• The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.

  Cancer 20110315

• Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib.

  Oncogene 20110310

• Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the '2011 ASCO Gastrointestinal Cancers Symposium'. San Francisco, CA, USA. January 20-22, 2011.

  JOP : Journal of the pancreas 20110309

• Osteonecrosis of the jaw related to sunitinib.

  Oral and maxillofacial surgery 20110301

• Marginal increase of sunitinib exposure by grapefruit juice.

  Cancer chemotherapy and pharmacology 20110301

• [Multimodal interventional therapy of a large renal cell carcinoma in a patient with high anesthesia risk - a case report].

  RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 20110301

• Sunitinib and other targeted therapies for renal cell carcinoma.

  British journal of cancer 20110301

• PET of αvbeta3-integrin and αvbeta5-integrin expression with 18F-fluciclatide for assessment of response to targeted therapy: ready for prime time?

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110301

• Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110301

• Spontaneous regression of metastatic renal cancer after short-term treatment with sunitinib.

  International journal of urology : official journal of the Japanese Urological Association 20110301

• A CT scan aspect of 'hypodense thyroid gland' after sunitinib treatment for metastatic carcinoma of the kidney.

  The Journal of clinical endocrinology and metabolism 20110301

• [Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies].

  Revue medicale de Liege 20110301

• [Current status in molecular-targeted therapy and IFNα for renal cell carcinoma in Japan].

  Hinyokika kiyo. Acta urologica Japonica 20110301

• Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110215

• Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.

  Cancer 20110215

• Current and emerging pharmacological treatments for gastrointestinal stromal tumour.

  Drugs 20110212

• Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

  The New England journal of medicine 20110210

• Promising advances in the treatment of malignant pancreatic endocrine tumors.

  The New England journal of medicine 20110210

• Osteonecrosis of the jaw and the role of macrophages.

  Journal of the National Cancer Institute 20110202

• Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy.

  European journal of radiology 20110201

• Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110201

• A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110201

• Hypothyroidism in patients with renal cell carcinoma: blessing or curse?

  Cancer 20110201

• Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

  Cancer 20110201

• Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110201

• Nasal metastases from renal cell carcinoma are associated with Memorial Sloan-Kettering Cancer Center poor-prognosis classification.

  Chinese journal of cancer 20110201

• [Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20110201

• The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

  Expert review of anticancer therapy 20110201

• Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.

  The oncologist 20110201

• Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.

  The oncologist 20110201

• Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.

  The oncologist 20110201

• The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma.

  British journal of cancer 20110118

• Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma.

  Urologic oncology 20110101

• An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib.

  Urologic oncology 20110101

• Targeting immune suppressing myeloid-derived suppressor cells in oncology.

  Critical reviews in oncology/hematology 20110101

• Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.

  BJU international 20110101

• Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.

  Urologic oncology 20110101

• Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells.

  Journal of neuro-oncology 20110101

• Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.

  Japanese journal of clinical oncology 20110101

• Molecular basis of hypertension side effects induced by sunitinib.

  Anti-cancer drugs 20110101

• The effect of sunitinib on immune subsets in metastatic clear cell renal cancer.

  Urologia internationalis 20110101

• Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature.

  Nephron. Clinical practice 20110101

• The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

  The Journal of urology 20110101

• VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment.

  Cancer research 20110101

• PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis.

  Cancer research 20110101

• Kidney cancer: Does hypothyroidism predict clinical outcome?

  Nature reviews. Urology 20110101

• Metastatic gastrointestinal stromal tumors.

  Cancer chemotherapy and pharmacology 20110101

• Management of a new isolated metastasis during sunitinib treatment in renal cell carcinoma patients: a lesson from two cases.

  Urologia internationalis 20110101

• Role of tyrosine kinase inhibitors in tumor immunology.

  Immunotherapy 20110101

• A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).

  Acta oncologica (Stockholm, Sweden) 20110101

• Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients.

  International journal of clinical pharmacology and therapeutics 20110101

• A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment.

  International journal of clinical pharmacology and therapeutics 20110101

• Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.

  Cancer chemotherapy and pharmacology 20110101

• Effect of sunitinib combined with ionizing radiation on endothelial cells.

  Journal of radiation research 20110101

• In pursuit of new anti-angiogenic therapies for cancer treatment.

  Frontiers in bioscience (Landmark edition) 20110101

• Therapeutic advances in women's cancers.

  Frontiers in bioscience (Scholar edition) 20110101

• A novel angiogenesis inhibitor, sunitinib malate, in encapsulating peritoneal sclerosis.

  Journal of nephrology 20110101

• Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences.

  Journal of computer assisted tomography 20110101

• Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.

  Neoplasia (New York, N.Y.) 20110101

• [AUO (Working Group on Urological Oncology) study of metastasized renal cell carcinoma: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma with or without adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 AUO)].

  Der Urologe. Ausg. A 20110101

• [Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel].

  Actas urologicas espanolas 20110101

• [Comment to: 'Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel'].

  Actas urologicas espanolas 20110101

• A 51-year-old man with rapidly progressive metastatic sarcomatoid renal cell carcinoma: an apparent complete clinical response to second-line therapy with sunitinib and low-dose interferon-alpha.

  Clinical advances in hematology & oncology : H&O 20110101

• Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases.

  General hospital psychiatry 20110101

• Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib.

  Biological & pharmaceutical bulletin 20110101

• Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.

  BMC cancer 20110101

• Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.

  The journal of supportive oncology 20110101

• [Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].

  Medicina 20110101

• Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy.

  International braz j urol : official journal of the Brazilian Society of Urology 20110101

• Development of an AlphaScreen-based high-throughput screening assay for inhibitors of human vascular endothelial growth factor receptor-3.

  Journal of immunoassay & immunochemistry 20110101

• [Use of sunitinib in metastatic renal cell carcinoma patients with poor prognosis].

  Voprosy onkologii 20110101

• Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.

  Oncology 20110101

• Efficacy of sunitinib rechallenge in kidney cancer: are mTOR inhibitors involved or is it only a matter of time?

  Onkologie 20110101

• Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC.

  Onkologie 20110101

• Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.

  Clinical drug investigation 20110101

• [Gastrointestinal stromal tumors].

  Annali italiani di chirurgia 20110101

• Angiogenesis in peritoneal dialysis.

  Kidney & blood pressure research 20110101

• Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.

  Breast cancer research : BCR 20110101

• New perspectives: role of Sunitinib in breast cancer.

  La Clinica terapeutica 20110101

• Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma.

  PloS one 20110101

• How to manage hypersensitivity reactions to biological agents?

  European journal of dermatology : EJD 20110101

• Metastatic collecting duct carcinoma of the kidney treated with sunitinib.

  World journal of surgical oncology 20110101

• Identification of novel therapeutic targets in microdissected clear cell ovarian cancers.

  PloS one 20110101

• Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.

  BMC cancer 20110101

• Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.

  Journal of translational medicine 20110101

• Targeted drug therapies and cancer.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101

• Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.

  Oncology 20110101

• Nilotinib is effective in imatinib and sunitinib resistant GIST: a case report.

  Hepato-gastroenterology 20110101

• [Evaluation of information about prophylactic treatment and management of hand-foot reactions caused by antiangiogenic therapies].

  Annales de dermatologie et de venereologie 20110101

• Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.

  Dermatologic therapy 20110101

• The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma.

  Journal of experimental & clinical cancer research : CR 20110101

• Improved curve fits to summary survival data: application to economic evaluation of health technologies.

  BMC medical research methodology 20110101

• Nilotinib in advanced gastrointestinal stromal tumors after imatinib and sunitinib therapy.

  Hepato-gastroenterology 20110101

• Sunitinib induced pyoderma gangrenosum-like ulcerations.

  European journal of medical research 20110101

• Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study.

  Cancer imaging : the official publication of the International Cancer Imaging Society 20110101

• Successful treatment with sunitinib in a young patient with metastatic gastrointestinal stromal tumor after failure on adjuvant imatinib.

  Journal of cancer research and therapeutics 20110101

• Successful treatment of T4 renal cell carcinoma after a neoadjuvant targeted therapy using sunitinib: report of a case.

  The Kurume medical journal 20110101

• HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.

  Cancer research 20101215

• Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.

  Cancer research 20101215

• Recurrent scrotal hemangiomas during treatment with sunitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101210

• Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.

  Investigational new drugs 20101201

• Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.

  American journal of clinical oncology 20101201

• SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20101201

• Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib.

  International journal of clinical oncology 20101201

• Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.

  Japanese journal of clinical oncology 20101201

• [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20101201

• Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma.

  Japanese journal of clinical oncology 20101201

• Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.

  Cancer 20101201

• Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

  European urology 20101201

• Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib.

  Lung cancer (Amsterdam, Netherlands) 20101201

• The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma.

  The Journal of urology 20101201

• Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia.

  Leukemia & lymphoma 20101201

• Sunitinib rechallenge in metastatic renal cell carcinoma patients.

  Cancer 20101201

• Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.

  Cancer research 20101201

• A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).

  The oncologist 20101201

• [Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].

  Magyar onkologia 20101201

• The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins.

  Anticancer research 20101201

• Efficacy of sunitinib in patients with renal cell carcinoma with bone metastases.

  Anticancer research 20101201

• Response and safety of sunitinib in a heavily pre-treated metastatic non-small cell lung carcinoma patient.

  Anticancer research 20101201

• More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus.

  Anticancer research 20101201

• Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives.

  Journal of medicinal chemistry 20101125

• Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

  Chemistry & biology 20101124

• Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.

  Cancer 20101115

• The cancer-HIV/AIDS treatment conundrum.

  Journal of the National Cancer Institute 20101103

• Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study.

  Lung cancer (Amsterdam, Netherlands) 20101101

• Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

  BJU international 20101101

• Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.

  BJU international 20101101

• Angiogenesis as a therapeutic target in urothelial carcinoma.

  Anti-cancer drugs 20101101

• Changes in resting energy expenditure (REE) as a function of tumor response to sunitinib in a cachexic patient with a metastatic endocrine tumor of the pancreas.

  Acta oncologica (Stockholm, Sweden) 20101101

• Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101101

• Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.

  European journal of medicinal chemistry 20101101

• A novel primary KIT exon 9 single nucleotide substitution c.1427G>T (p.Ser476Ile) in a gastrointestinal stromal tumor.

  Virchows Archiv : an international journal of pathology 20101101

• Progression of intramedullary metastasis during perioperative cessation of sunitinib.

  Nature reviews. Urology 20101101

• [Multimodality therapy concepts for soft tissue sarcomas].

  Der Internist 20101101

• Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules.

  Expert opinion on biological therapy 20101101

• ¹¹C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy.

  BJU international 20101101

• Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.

  Cancer treatment reviews 20101101

• mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo.

  Cancer letters 20101028

• [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].

  Orvosi hetilap 20101024

• Risk of arterial thrombosis not increased by sorafenib or sunitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101020

• Novel azulene-based derivatives as potent multi-receptor tyrosine kinase inhibitors.

  Bioorganic & medicinal chemistry letters 20101015

• Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.

  British journal of cancer 20101012

• A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101010

• Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.

  Investigational new drugs 20101001

• An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines.

  Investigational new drugs 20101001

• Phase II study of sunitinib malate in head and neck squamous cell carcinoma.

  Investigational new drugs 20101001

• Gastrointestinal stromal tumors: current management.

  Journal of surgical oncology 20101001

• The potential role of sunitinib in gastrointestinal cancers other than GIST.

  Critical reviews in oncology/hematology 20101001

• The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.

  Japanese journal of clinical oncology 20101001

• Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.

  Cancer investigation 20101001

• Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.

  American journal of ophthalmology 20101001

• Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells.

  Toxicology and applied pharmacology 20101001

• Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling.

  International journal of radiation oncology, biology, physics 20101001

• Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to sunitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101001

• SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells.

  Cancer biology & therapy 20101001

• Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies.

  Cancer investigation 20101001

• Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20101001

• Evidence-based urology in practice: randomized controlled trials stopped early for benefit.

  BJU international 20101001

• Deciphering the anticancer mechanisms of sunitinib.

  Cancer biology & therapy 20101001

• Recall pneumonitis during systemic treatment with sunitinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20101001

• Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?

  American journal of hematology 20101001

• Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun?

  Hypertension (Dallas, Tex. : 1979) 20101001

• Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.

  Hypertension (Dallas, Tex. : 1979) 20101001

• [Leg ulcerations and sunitinib].

  Annales de dermatologie et de venereologie 20101001

• [Molecular targeted therapy for renal cell carcinoma and other urological cancers].

  Nihon rinsho. Japanese journal of clinical medicine 20101001

• Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.

  The Israel Medical Association journal : IMAJ 20101001

• [Clinical manifestation of targeted drugs in individualized therapy of malignant tumors].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20101001

• A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.

  British journal of cancer 20100928

• Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.

  The Biochemical journal 20100915

• Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.

  British journal of cancer 20100907

• Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.

  Medical oncology (Northwood, London, England) 20100901

• Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.

  Medical oncology (Northwood, London, England) 20100901

• Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature.

  Medical oncology (Northwood, London, England) 20100901

• Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.

  International journal of cancer 20100901

• Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.

  Cancer chemotherapy and pharmacology 20100901

• Pharmacokinetics of sunitinib malate in subjects with hepatic impairment.

  Cancer chemotherapy and pharmacology 20100901

• Angiogenic blockade and radiotherapy in hepatocellular carcinoma.

  International journal of radiation oncology, biology, physics 20100901

• Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100901

• Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.

  BJU international 20100901

• Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.

  World journal of surgery 20100901

• Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100901

• Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100901

• Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.

  Thyroid : official journal of the American Thyroid Association 20100901

• Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma.

  The Journal of urology 20100901

• Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.

  Breast cancer research and treatment 20100901

• Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100901

• Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume.

  The Tohoku journal of experimental medicine 20100901

• Sunitinib for metastatic renal cell carcinoma.

  Future oncology (London, England) 20100901

• [A case of recurrent intracaval renal cell carcinoma effectively treated with sunitinib].

  Hinyokika kiyo. Acta urologica Japonica 20100901

• Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice.

  Anticancer research 20100901

• Myelosuppression by sunitinib is flt-3 genotype dependent.

  British journal of cancer 20100824

• Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors.

  International journal of cancer 20100815

• Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100810

• Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors.

  Investigational new drugs 20100801

• Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100801

• MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.

  Neuro-oncology 20100801

• Current and predicted cost of metastatic renal cell carcinoma in Finland.

  Acta oncologica (Stockholm, Sweden) 20100801

• Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.

  Leukemia 20100801

• Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation.

  Chemical biology & drug design 20100801

• Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.

  Radiology 20100801

• The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe?

  BJU international 20100801

• Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.

  Oncology reports 20100801

• Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.

  Acta oncologica (Stockholm, Sweden) 20100801

• Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity.

  Toxicologic pathology 20100801

• [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].

  Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20100801

• Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.

  Expert opinion on drug metabolism & toxicology 20100801

• Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100801

• Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

  Clinical lymphoma, myeloma & leukemia 20100801

• A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.

  Journal of clinical pharmacy and therapeutics 20100801

• Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo.

  Cancer letters 20100728

• Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells.

  Biochemical and biophysical research communications 20100723

• Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.

  Bioorganic & medicinal chemistry 20100715

• Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.

  British journal of cancer 20100713

• Comparison of conventional time-intensity curves vs. maximum intensity over time for post-processing of dynamic contrast-enhanced ultrasound.

  European journal of radiology 20100701

• Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

  Cancer chemotherapy and pharmacology 20100701

• An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100701

• Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy.

  Cancer chemotherapy and pharmacology 20100701

• New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?

  Current opinion in oncology 20100701

• SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK).

  Cancer biology & therapy 20100701

• Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.

  The oncologist 20100701

• Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors.

  Bioorganic & medicinal chemistry 20100701

• Close encounters of a novel kind: a multi-targeted cancer drug meets a metabolic sensor.

  Cancer biology & therapy 20100701

• Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.

  Molecular cancer therapeutics 20100701

• Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100701

• [Efficacy of tyrosine kinase inhibitor therapy combined with surgical resection in patients with metastatic gastrointestinal stromal tumor].

  Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20100701

• [The role of pathologists in the target therapy of gastrointestinal tumors].

  Zhonghua bing li xue za zhi = Chinese journal of pathology 20100701

• Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100615

• Molecular basis and management of gastrointestinal stromal tumors.

  World journal of gastroenterology 20100614

• Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100610

• Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.

  British journal of cancer 20100608

• Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.

  Medical oncology (Northwood, London, England) 20100601

• Olecranon bursitis in patients treated with sunitinib for renal cell carcinoma.

  Medical oncology (Northwood, London, England) 20100601

• Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.

  American journal of clinical oncology 20100601

• Update on systemic therapies of metastatic renal cell carcinoma.

  World journal of urology 20100601

• Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene.

  Cancer science 20100601

• ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100601

• Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.

  The Journal of clinical endocrinology and metabolism 20100601

• Improvement of psoriasis during sunitinib therapy for renal cell carcinoma.

  The American journal of the medical sciences 20100601

• Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach.

  World journal of urology 20100601

• [Antiangionic drugs in soft tissue sarcoma].

  Bulletin du cancer 20100601

• [Focus on GIST management].

  Bulletin du cancer 20100601

• Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20100601

• Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.

  AJR. American journal of roentgenology 20100601

• Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.

  Molecular cancer therapeutics 20100601

• Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.

  The Journal of clinical endocrinology and metabolism 20100601

• [Treatment with antiangiogenic drugs].

  Nihon rinsho. Japanese journal of clinical medicine 20100601

• [Anti-angiogenic drugs].

  Nihon rinsho. Japanese journal of clinical medicine 20100601

• Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer.

  Thyroid : official journal of the American Thyroid Association 20100601

• Renal cell carcinoma: ten years of significant advances.

  Targeted oncology 20100601

• Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.

  Oncogene 20100520

• Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation.

  Blood 20100520

• Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents.

  Bioorganic & medicinal chemistry 20100515

• Tyrosine kinase inhibitors and acute pancreatitis.

  JOP : Journal of the pancreas 20100505

• Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100501

• The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.

  Urology 20100501

• Tumor response to sunitinib malate observed in clear-cell sarcoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100501

• Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.

  Acta oncologica (Stockholm, Sweden) 20100501

• Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib.

  Kidney international 20100501

• Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.

  Breast cancer research and treatment 20100501

• Inhibition of gamma-secretase by the CK1 inhibitor IC261 does not depend on CK1delta.

  Bioorganic & medicinal chemistry letters 20100501

• Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100501

• Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers.

  Clinical pharmacology and therapeutics 20100501

• The promise of biomarkers for personalized renal cancer care.

  Kidney international 20100501

• Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.

  Cancer research 20100501

• Editorial comment.

  Urology 20100501

• Editorial comment.

  Urology 20100501

• Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.

  Molecular cancer therapeutics 20100501

• [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

  Aktuelle Urologie 20100501

• Necrosis of a skin autograft after short-term treatment with sunitinib in a 14-year-old girl with metastatic alveolar soft part sarcoma of the thigh.

  Klinische Padiatrie 20100501

• Current management of GISTs.

  Clinical advances in hematology & oncology : H&O 20100501

• Present state of target therapy for disseminated renal cell carcinoma.

  Immunotherapy 20100501

• The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity.

  Toxicology and applied pharmacology 20100415

• Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors.

  British journal of cancer 20100413

• Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.

  Investigational new drugs 20100401

• Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function.

  Journal of clinical pharmacology 20100401

• Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate.

  Journal of neuro-oncology 20100401

• Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice.

  Clinical immunology (Orlando, Fla.) 20100401

• Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib.

  Anti-cancer drugs 20100401

• Drug binding and resistance mechanism of KIT tyrosine kinase revealed by hydrogen/deuterium exchange FTICR mass spectrometry.

  Protein science : a publication of the Protein Society 20100401

• Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance.

  Journal of biochemistry 20100401

• Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.

  The Lancet. Oncology 20100401

• Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice.

  The Journal of clinical investigation 20100401

• Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.

  Journal of chemotherapy (Florence, Italy) 20100401

• NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.

  Journal of the National Comprehensive Cancer Network : JNCCN 20100401

• [Neoadjuvant treatment and breast conserving surgery - a success of clinical research in breast cancer].

  Wiener medizinische Wochenschrift (1946) 20100401

• Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.

  British journal of cancer 20100330

• Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer.

  International journal of cancer 20100315

• Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application.

  Journal of pharmaceutical and biomedical analysis 20100311

• Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20100311

• Phase II study of sunitinib in patients with metastatic urothelial cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100310

• Neuroendocrine tumors of the pancreas: what's new. Highlights from the '2010 ASCO Gastrointestinal Cancers Symposium'. Orlando, FL, USA. January 22-24, 2010.

  JOP : Journal of the pancreas 20100305

• Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.

  British journal of cancer 20100302

• Sunitinib-induced hand-foot syndrome: a new, distinct form.

  Clinical and experimental dermatology 20100301

• A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.

  Cancer chemotherapy and pharmacology 20100301

• Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.

  Journal of cancer research and clinical oncology 20100301

• A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.

  Japanese journal of clinical oncology 20100301

• [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].

  Aktuelle Urologie 20100301

• [Gastrointestinal stromal tumors: evolution of a tumor concept from unclassifiable neoplasms to targeted molecular therapy].

  Der Pathologe 20100301

• Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100301

• Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100301

• Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?

  Thyroid : official journal of the American Thyroid Association 20100301

• Colony stimulating factor-1 receptor as a target for small molecule inhibitors.

  Bioorganic & medicinal chemistry 20100301

• How does sunitinib cause hypothyroidism?

  Thyroid : official journal of the American Thyroid Association 20100301

• Sunitinib induces hypothyroidism with a markedly reduced vascularity.

  Thyroid : official journal of the American Thyroid Association 20100301

• Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).

  The oncologist 20100301

• [Recent progress in the molecular-targeting treatment of neuroendocrine tumors].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20100301

• Sunitinib for the management of advanced renal cell carcinoma.

  Expert review of anticancer therapy 20100301

• Molecular response prediction in gastrointestinal stromal tumors.

  Targeted oncology 20100301

• A new prognostic score derived from phase I study participants with advanced solid tumours is also valid in patients with brain metastasis.

  Anticancer research 20100301

• [Clinical study of Sunitinib in the treatment of metastatic renal clear cell carcinoma: a single center 23 cases experience].

  Zhonghua wai ke za zhi [Chinese journal of surgery] 20100301

• FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

  Blood 20100218

• Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis.

  British journal of cancer 20100216

• Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma.

  International journal of cancer 20100215

• Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.

  Bioorganic & medicinal chemistry 20100215

• Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100215

• Sorafenib-associated remission of psoriasis in hypernephroma: case report.

  Dermatology online journal 20100215

• Novel 3-arylideneindolin-2-ones as inhibitors of NAD+ -dependent histone deacetylases (sirtuins).

  Journal of medicinal chemistry 20100211

• Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma.

  Journal of the European Academy of Dermatology and Venereology : JEADV 20100201

• Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.

  Cancer letters 20100201

• Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100201

• Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100201

• A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.

  Gynecologic oncology 20100201

• Successful desensitization protocol for hypersensitivity reaction caused by sunitinib in a patient with a gastrointestinal stromal tumor.

  Japanese journal of clinical oncology 20100201

• Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate.

  Annals of surgical oncology 20100201

• Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy.

  Cancer treatment reviews 20100201

• VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100201

• Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.

  Anti-cancer drugs 20100201

• Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib.

  Anti-cancer drugs 20100201

• Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34.

  The Journal of urology 20100201

• Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.

  Cancer research 20100201

• Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.

  Cancer research 20100201

• Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy.

  The Annals of pharmacotherapy 20100201

• Seven 3-methylidene-1H-indol-2(3H)-ones related to the multiple-receptor tyrosine kinase inhibitor sunitinib.

  Acta crystallographica. Section C, Crystal structure communications 20100201

• Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?

  The oncologist 20100201

• Risk of bleeding not increased by sorafenib or sunitinib.

  The Lancet. Oncology 20100201

• Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU.

  The oncologist 20100201

• Prognostic factors in patients treated with VEGF-targeted therapies.

  Clinical advances in hematology & oncology : H&O 20100201

• [Treatment of locally advanced renal tumors].

  Actas urologicas espanolas 20100201

• Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature.

  Endocrine 20100201

• Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.

  British journal of cancer 20100105

• SUN vs BEVthornIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival.

  British journal of cancer 20100105

• Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor.

  Acta oncologica (Stockholm, Sweden) 20100101

• Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention.

  Urologic oncology 20100101

• Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice.

  International immunopharmacology 20100101

• Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100101

• Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100101

• Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management.

  Acta oncologica (Stockholm, Sweden) 20100101

• About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?

  Annals of oncology : official journal of the European Society for Medical Oncology 20100101

• Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100101

• CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.

  Cancer biology & therapy 20100101

• Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20100101

• Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.

  AJR. American journal of roentgenology 20100101

• Compounds in clinical Phase III and beyond.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101

• Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways.

  Molecular cancer research : MCR 20100101

• Sunitinib.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101

• Progress in the management of advanced renal cell carcinoma (RCC).

  Aktuelle Urologie 20100101

• Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma.

  Histopathology 20100101

• Anti-cancer drugs. Editorial.

  Anti-cancer drugs 20100101

• Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma.

  Anti-cancer drugs 20100101

• Renal cell carcinoma: complete response.

  Anti-cancer drugs 20100101

• Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma.

  Anti-cancer drugs 20100101

• Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient.

  Anti-cancer drugs 20100101

• Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.

  Anti-cancer drugs 20100101

• [Renal cell carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.

  Journal of translational medicine 20100101

• Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.

  BMC cancer 20100101

• [The introduction of targeted drugs].

  Onkologie 20100101

• [Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma].

  Onkologie 20100101

• [First-line therapy of metastatic renal cell carcinoma--update 2009].

  Onkologie 20100101

• [Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].

  Onkologie 20100101

• [Sunitinib in clinical practice: the expanded access program for metastatic renal cell carcinoma].

  Onkologie 20100101

• [Monitoring of metastatic renal cell carcinoma--standards and challenges].

  Onkologie 20100101

• [Outlook: Future therapy of renal cell carcinoma].

  Onkologie 20100101

• Plasma N-terminal pro-brain natriuretic peptide as prognostic marker in fatal cardial decompensation with sunitinib malate therapy.

  Urologia internationalis 20100101

• Downsizing a tumor thrombus of advanced renal cell carcinoma with neoadjuvant systemic therapy and resulting histopathological effects.

  Urologia internationalis 20100101

• New therapeutic strategies for renal cell carcinoma.

  Urologic nursing 20100101

• [Targeted therapies in hepatocellular carcinoma].

  Presse medicale (Paris, France : 1983) 20100101

• Optimal use of targeted agents for advanced gastrointestinal stromal tumours.

  Oncology 20100101

• [Renal cell carcinoma management and therapies in 2010].

  Bulletin du cancer 20100101

• [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].

  Bulletin du cancer 20100101

• [Targeted therapies: sequential and combined treatments].

  Bulletin du cancer 20100101

• [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].

  Bulletin du cancer 20100101

• [Advanced renal carcinomas with special situations. How to treat them?].

  Bulletin du cancer 20100101

• Leptomeningeal carcinomatosis from renal cell cancer: treatment attempt with radiation and sunitinib (case report).

  World journal of surgical oncology 20100101

• [Interests in angiogenesis inhibitor drugs approved for the treatment of cancers].

  Therapie 20100101

• Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.

  PloS one 20100101

• Abscess formation mimicking disease progression, in a patient with metastatic renal cell carcinoma during sunitinib treatment.

  World journal of surgical oncology 20100101

• Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.

  Onkologie 20100101

• How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100101

• Targeted treatment for metastatic renal cell carcinoma and immune regulation.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20100101

• The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment.

  PloS one 20100101

• Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.

  Genome biology 20100101

• Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?

  Hepato-gastroenterology 20100101

• Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.

  Endocrine journal 20100101

• Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma.

  BMC cancer 20100101

• Prolonged response to cytoreductive surgery and sunitinib in an elderly patient with synchronous multiple metastases from renal cell carcinoma.

  Tumori 20100101

• A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20100101

• New perspectives: role of sunitinib in breast cancer.

  La Clinica terapeutica 20100101

• Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice.

  BMC pharmacology 20100101

• Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate.

  Urologia internationalis 20100101

• Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report.

  Urologia internationalis 20100101

• Vesicocutaneous fistula formation during treatment with sunitinib malate: Case report.

  BMC gastroenterology 20100101

• [Hand-foot syndrome after administration of tyrosinkinase inhibitors].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20100101

• Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.

  Journal of medical economics 20100101

• Antiangiogenic therapy for breast cancer.

  Breast cancer research : BCR 20100101

• Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.

  Oncology 20100101

• Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma.

  Chemotherapy 20100101

• Head and neck squamous cell carcinoma: new translational therapies.

  The Mount Sinai journal of medicine, New York 20100101

• Cyclooxygenase-2 expression in gastrointestinal stromal tumours.

  Asian Pacific journal of cancer prevention : APJCP 20100101

• Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib.

  BMC cancer 20100101

• Intermittent treatment with sunitinib may achieve complete response in metastatic renal cell carcinoma.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20100101

• Perspectives in the development of novel treatment approaches.

  Tumori 20100101

• [Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20100101

• Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease.

  Journal of cancer research and therapeutics 20100101

• Metastatic paraganglioma and treatment with sunitinib: a case report.

  Tumori 20100101

• The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro.

  Journal of immunology (Baltimore, Md. : 1950) 20091215

• Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.

  Journal of medicinal chemistry 20091210

• Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091210

• Sunitinib-induced thyrotoxicosis.

  Journal of endocrinological investigation 20091201

• Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes.

  Cancer treatment reviews 20091201

• [Internal medical therapy of gastrointestinal stroma tumors].

  Der Radiologe 20091201

• Clinical pharmacokinetics of tyrosine kinase inhibitors.

  Cancer treatment reviews 20091201

• Biochemical and pathological response of prostate cancer in a patient with metastatic renal cell carcinoma on sunitinib treatment.

  Japanese journal of clinical oncology 20091201

• Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

  Gynecologic oncology 20091201

• Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091201

• N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.

  Bioorganic & medicinal chemistry letters 20091201

• Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array.

  British journal of cancer 20091201

• Sunitinib paves the way for targeted therapies in neuroendocrine tumors.

  Targeted oncology 20091201

• [Aspects of surgical treatment for gastro-intestinal stromal tumors].

  Der Radiologe 20091201

• Tyrosine kinase inhibitors and the thyroid.

  Best practice & research. Clinical endocrinology & metabolism 20091201

• Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?

  Nature reviews. Clinical oncology 20091201

• Metastatic renal cell carcinoma: current standards of care.

  Clinical journal of oncology nursing 20091201

• Management of vascular endothelial growth factor and multikinase inhibitor side effects.

  Clinical journal of oncology nursing 20091201

• Health policy: The UK 'postcode lottery' in renal cell carcinoma.

  Nature reviews. Urology 20091201

• Tyrosine kinase inhibitor-induced macrocytosis.

  Anticancer research 20091201

• Targeted molecular therapies in thyroid carcinoma.

  Arquivos brasileiros de endocrinologia e metabologia 20091201

• [Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].

  Lakartidningen 20091201

• Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.

  British journal of cancer 20091117

• Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091115

• Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091115

• Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer.

  British journal of cancer 20091103

• Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.

  Annals of oncology : official journal of the European Society for Medical Oncology 20091101

• Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.

  The British journal of dermatology 20091101

• Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D(3).

  Leukemia 20091101

• [An image of vena cava thrombosis].

  Journal des maladies vasculaires 20091101

• Induced-fit docking studies of the active and inactive states of protein tyrosine kinases.

  Journal of molecular graphics & modelling 20091101

• A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091101

• Advances in personalized therapeutics in non-small cell lung cancer: 4q12 amplification, PDGFRA oncogene addiction and sunitinib sensitivity.

  Cancer biology & therapy 20091101

• Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.

  Journal of the American Academy of Dermatology 20091101

• A case of advanced medullary thyroid carcinoma successfully treated with sunitinib.

  The oncologist 20091101

• Therapy for metastatic RCC--questions remain.

  Nature reviews. Urology 20091101

• Effect of sunitinib on renal cell carcinoma cutaneous metastasis.

  International journal of dermatology 20091101

• Everolimus: in advanced renal cell carcinoma.

  Drugs 20091022

• Recombinant peptides as biomarkers for tumor response to molecular targeted therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091015

• Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.

  British journal of cancer 20091006

• A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20091001

• Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model.

  Annals of oncology : official journal of the European Society for Medical Oncology 20091001

• Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.

  Anti-cancer drugs 20091001

• AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

  Blood 20091001

• Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20091001

• Neurological adverse effects caused by cytotoxic and targeted therapies.

  Nature reviews. Clinical oncology 20091001

• Estimation of tumor microvessel density by MRI using a blood pool contrast agent.

  International journal of oncology 20091001

• An overview of small-molecule inhibitors of VEGFR signaling.

  Nature reviews. Clinical oncology 20091001

• Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

  The Lancet. Oncology 20091001

• A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091001

• Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091001

• Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.

  Clinical genitourinary cancer 20091001

• A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib.

  Clinical genitourinary cancer 20091001

• Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer.

  Expert review of anticancer therapy 20091001

• Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090920

• Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090915

• Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090915

• Biomarkers in GIST: partly ready for prime-time use.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090915

• Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090915

• MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.

  Genes & development 20090915

• Long-term response in primary renal cancer to sequential antiangiogenic therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090910

• Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090910

• Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report.

  JOP : Journal of the pancreas 20090904

• Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al.

  Clinical endocrinology 20090901

• Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.

  Cancer chemotherapy and pharmacology 20090901

• Statin therapy as the fundamental therapy for cardiovascular prevention: be careful.

  Clinical endocrinology 20090901

• Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma.

  Journal of neurosurgery 20090901

• Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.

  European journal of cancer (Oxford, England : 1990) 20090901

• Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090901

• Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.

  Current opinion in supportive and palliative care 20090901

• Targeted therapies in the treatment of advanced/metastatic NSCLC.

  European journal of cancer (Oxford, England : 1990) 20090901

• Surgical resection of renal cell carcinoma after targeted therapy.

  The Journal of urology 20090901

• Subdural collections arising from calvarial metastases following discontinuation of anti-angiogenic therapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090901

• Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors.

  Bioorganic & medicinal chemistry letters 20090901

• Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090901

• Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.

  Neoplasia (New York, N.Y.) 20090901

• Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.

  Current cancer drug targets 20090901

• Advances in the treatment of gastrointestinal stromal tumor.

  Advances in therapy 20090901

• Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer.

  Health technology assessment (Winchester, England) 20090901

• [Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090901

• In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives.

  Bioorganic & medicinal chemistry letters 20090815

• Blackberry-induced hand-foot skin reaction to sunitinib.

  Investigational new drugs 20090801

• Major response to sunitinib (Sutene) in metastatic malignant phyllodes tumor of breast.

  Investigational new drugs 20090801

• Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.

  World journal of urology 20090801

• Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors.

  Cancer chemotherapy and pharmacology 20090801

• Effective therapy for metastatic renal cancer, whither to now.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090801

• Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090801

• Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response.

  Cancer 20090801

• Re: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. A. A. Thomas, B. I. Rini, B. R. Lane, J. Garcia, R. Dreicer, E. A. Klein, A. C. Novick And S. C. Campbell. J Urol 2009; 181: 518-523.

  The Journal of urology 20090801

• Adverse effects of anticancer agents that target the VEGF pathway.

  Nature reviews. Clinical oncology 20090801

• Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

  The Lancet. Oncology 20090801

• Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

  The Lancet. Oncology 20090801

• Sunitinib in renal-cell carcinoma: expanded indications.

  The Lancet. Oncology 20090801

• Sunitinib and the benefits of a negative study.

  The Lancet. Oncology 20090801

• Sorafenib and sunitinib.

  The oncologist 20090801

• Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.

  Clinical genitourinary cancer 20090801

• A differential response to sunitinib: sustained systemic response paralleled by intra-dural progression in the spine. Should standard response criteria be reviewed?

  Clinical genitourinary cancer 20090801

• [Establishment of homogeneous time-resolved fluorescence immunoassay for high throughput screening of protein tyrosine kinase inhibitors].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20090801

• Sunitinib in breast cancer: friend or foe.

  Breast (Edinburgh, Scotland) 20090801

• Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer.

  Breast (Edinburgh, Scotland) 20090801

• Bevacizumab + sunitinib: microangiopathic haemolytic anaemia. A serious drug interaction between 2 cancer drugs.

  Prescrire international 20090801

• Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.

  British journal of cancer 20090721

• Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090715

• Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma.

  International journal of radiation oncology, biology, physics 20090715

• Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.

  European urology 20090701

• Hits and misses in targeting pediatric cancers.

  Pediatric blood & cancer 20090701

• Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

  European journal of cancer (Oxford, England : 1990) 20090701

• Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.

  Pediatric blood & cancer 20090701

• Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.

  BJU international 20090701

• Sequential sorafenib and sunitinib for renal cell carcinoma.

  The Journal of urology 20090701

• Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090701

• VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.

  Cancer biology & therapy 20090701

• Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.

  Oncology reports 20090701

• Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.

  Nature reviews. Urology 20090701

• Sunitinib-aggravated hypertension.

  Journal of hypertension 20090701

• The nasal septum: an unusual presentation of metastatic renal cell carcinoma.

  The Journal of craniofacial surgery 20090701

• Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group.

  Clinical nephrology 20090701

• Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

  Cancer letters 20090628

• Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.

  Clinica chimica acta; international journal of clinical chemistry 20090627

• Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090620

• How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.

  Journal of the National Cancer Institute 20090616

• Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.

  European urology 20090601

• Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.

  European urology 20090601

• Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.

  Neuro-oncology 20090601

• Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma.

  European urology 20090601

• Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits.

  Birth defects research. Part B, Developmental and reproductive toxicology 20090601

• Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090601

• Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis.

  The Journal of urology 20090601

• Sunitinib in solid tumors.

  Expert opinion on investigational drugs 20090601

• 'Sunitinib withdrawal phenomenon' or spontaneous regression in renal cell cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090601

• Early detection of hypertension in a patient treated with sunitinib by measuring cardio-ankle vascular index.

  The Tohoku journal of experimental medicine 20090601

• Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.

  Expert review of anticancer therapy 20090601

• Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib.

  Nature reviews. Urology 20090601

• The role of antiangiogenesis therapy: bevacizumab and beyond.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20090601

• Cardiac magnetic resonance imaging in sunitinib malate-related cardiomyopathy: no late gadolinium enhancement.

  Journal of the Chinese Medical Association : JCMA 20090601

• New study sheds light on angiogenesis inhibitors.

  ONS connect 20090601

• Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib.

  Journal of chemotherapy (Florence, Italy) 20090601

• Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20090601

• Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.

  Journal of medicinal chemistry 20090528

• Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.

  Cancer letters 20090518

• Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.

  Cancer 20090515

• Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090515

• Inhibitory effects of sunitinib on ovalbumin-induced chronic experimental asthma in mice.

  Chinese medical journal 20090505

• Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.

  Critical reviews in oncology/hematology 20090501

• Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.

  Cancer treatment reviews 20090501

• Tolerability of first-line therapy for metastatic renal cell carcinoma.

  Cancer treatment reviews 20090501

• Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma.

  Japanese journal of clinical oncology 20090501

• Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.

  International journal of urology : official journal of the Japanese Urological Association 20090501

• [Targeted therapies and their indications in solid neoplasias].

  La Revue de medecine interne 20090501

• [Potential role of antiangiogenic treatment in neuroblastoma].

  Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 20090501

• Progress in the treatment of neuroendocrine tumors.

  Current oncology reports 20090501

• Targeted therapies in metastatic renal cancer in 2009.

  BJU international 20090501

• [Necrotizing hand-foot skin reaction induced by antiangiogenic in a patient with Thevenard neuroacropathy].

  Journal des maladies vasculaires 20090501

• Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.

  Cancer research 20090501

• Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.

  Current cardiology reports 20090501

• Reversible posterior leucoencephalopathy syndrome associated with sunitinib.

  Internal medicine journal 20090501

• Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.

  Journal of magnetic resonance imaging : JMRI 20090501

• Phase II study of sunitinib in men with advanced prostate cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090501

• Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090501

• In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model.

  Neoplasia (New York, N.Y.) 20090501

• Prognostic markers and new, innovative treatments in renal cell carcinoma.

  Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20090501

• Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?

  Thyroid : official journal of the American Thyroid Association 20090501

• Expanding the boundaries of clinical practice: building on experience with targeted therapies.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090501

• New paradigms in gastrointestinal stromal tumour management.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090501

• Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090501

• Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment.

  Molecular cancer therapeutics 20090501

• Management of cardiac adverse events occurring with sunitinib treatment.

  Anticancer research 20090501

• Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model.

  Cancer biology & therapy 20090501

• Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature.

  Journal of cutaneous pathology 20090501

• Angiogenesis regulated by VEGF and its receptors and its clinical application.

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20090501

• Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.

  British journal of cancer 20090407

• Acute hepatic failure following monotherapy with sunitinib for ovarian cancer.

  Cancer chemotherapy and pharmacology 20090401

• Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis.

  Urology 20090401

• A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090401

• Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.

  Pharmacotherapy 20090401

• Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

  Nature reviews. Clinical oncology 20090401

• Treatment of gastrointestinal stromal tumours: imatinib, sunitinib -- and then?

  Expert opinion on investigational drugs 20090401

• Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine.

  The Annals of pharmacotherapy 20090401

• Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis.

  Cancer prevention research (Philadelphia, Pa.) 20090401

• NICE celebrates 10th anniversary amid renal cancer drug controversy.

  BJU international 20090401

• Hypofractionated radiotherapy with concomitant sunitinib - is there a radiosensitizing effect?

  The Canadian journal of urology 20090401

• [Pharmacology profile of sunitinib malate (Sutent) Capsules) and clinical findings on this drug].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20090401

• Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.

  Targeted oncology 20090401

• Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene.

  International journal of clinical oncology 20090401

• Renal toxicity of targeted therapies.

  Targeted oncology 20090401

• From theoretical synergy to clinical supra-additive toxicity.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090320

• Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090320

• Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy.

  International journal of cancer 20090315

• Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.

  Cancer research 20090315

• Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090315

• The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

  Cancer research 20090315

• Sunitinib-induced hemoglobin changes are related to the dosing schedule.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090310

• Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

  Cancer cell 20090303

• Pharmacokinetics of sunitinib in an obese patient with a GIST.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090301

• Metastatic adrenocortical carcinoma treated with sunitinib: a case report.

  Japanese journal of clinical oncology 20090301

• Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?

  Annals of oncology : official journal of the European Society for Medical Oncology 20090301

• N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.

  Bioorganic & medicinal chemistry letters 20090301

• Sunitinib adverse event: oral bullous and lichenoid mucositis.

  The Annals of pharmacotherapy 20090301

• Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.

  Cancer chemotherapy and pharmacology 20090301

• Recent advances in the systemic treatment of metastatic papillary renal cancer.

  Expert review of anticancer therapy 20090301

• Tyrosine kinase inhibitors in treatment of fibrous histiocytoma.

  Experimental oncology 20090301

• Sunitinib-induced myxedema coma.

  The American journal of emergency medicine 20090301

• Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.

  Clinical lung cancer 20090301

• Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.

  International journal of cancer 20090215

• A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.

  Cancer 20090215

• NICE recommends kidney cancer drug it previously rejected on cost grounds.

  BMJ (Clinical research ed.) 20090209

• Metastatic renal cell carcinoma with partial response to sunitinib complicated by ureteral obstruction from necrotic tumor.

  Urology 20090201

• Editorial comment on: Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor.

  European urology 20090201

• Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma.

  Investigational new drugs 20090201

• Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.

  Drug metabolism and disposition: the biological fate of chemicals 20090201

• Vascular endothelial growth factor and angiopoietin-2 play a major role in the pathogenesis of vascular leakage in cirrhotic rats.

  Gut 20090201

• Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.

  The Journal of clinical endocrinology and metabolism 20090201

• Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090201

• Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090201

• Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.

  The Journal of urology 20090201

• Treatment of hemodialyzed patient with sunitinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090201

• Response to sunitinib malate in advanced alveolar soft part sarcoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090201

• 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.

  Cancer biotherapy & radiopharmaceuticals 20090201

• Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase.

  Clinical and translational science 20090201

• Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090120

• Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090120

• Molecular therapy for the treatment of hepatocellular carcinoma.

  British journal of cancer 20090113

• Activity of sunitinib in patients with advanced neuroendocrine tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090110

• Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090110

• Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20090101

• Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.

  Urologic oncology 20090101

• Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.

  Journal of cancer research and clinical oncology 20090101

• Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.

  Acta oncologica (Stockholm, Sweden) 20090101

• Pharmacokinetics of sunitinib in hemodialysis.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090101

• Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma.

  European urology 20090101

• Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma.

  Bone 20090101

• Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas.

  Molecular therapy : the journal of the American Society of Gene Therapy 20090101

• Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.

  The Journal of clinical endocrinology and metabolism 20090101

• Pre-surgical targeted molecular therapy in renal cell carcinoma.

  BJU international 20090101

• Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.

  Cancer 20090101

• Early development of sunitinib in hepatocellular carcinoma.

  Expert review of anticancer therapy 20090101

• Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors.

  Acta oncologica (Stockholm, Sweden) 20090101

• Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.

  The oncologist 20090101

• Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.

  BMC cancer 20090101

• [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

  Aktuelle Urologie 20090101

• [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].

  Aktuelle Urologie 20090101

• Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report.

  Chemotherapy 20090101

• Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib.

  Acta oncologica (Stockholm, Sweden) 20090101

• Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib.

  Angiogenesis 20090101

• Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.

  Clinical genitourinary cancer 20090101

• Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.

  Clinical genitourinary cancer 20090101

• Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma.

  Clinical genitourinary cancer 20090101

• Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma.

  Clinical genitourinary cancer 20090101

• Compassionate use of sorafenib in patients with advanced renal cell cancer.

  Clinical genitourinary cancer 20090101

• Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib.

  Clinical genitourinary cancer 20090101

• Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib.

  Clinical genitourinary cancer 20090101

• Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20090101

• Prolonged use of the tyrosine kinase inhibitor in a peritoneal dialysis patient with metastatic renal cell carcinoma: possible beneficial effects on peritoneal membrane and peritonitis rates.

  International urology and nephrology 20090101

• Perioperative treatment of gastrointestinal stromal tumors.

  Oncology (Williston Park, N.Y.) 20090101

• Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?

  Oncology (Williston Park, N.Y.) 20090101

• Controversies in the surgical management of GIST in the era of imatinib.

  Oncology (Williston Park, N.Y.) 20090101

• Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.

  BMC cancer 20090101

• Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.

  Oncology 20090101

• Toxic dermatolysis, tissue necrosis and impaired wound healing due to sunitinib treatment leading to forefoot amputation.

  Urologia internationalis 20090101

• Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure due to heart metastases from renal cell carcinoma.

  Cardiology 20090101

• The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.

  Acta oncologica (Stockholm, Sweden) 20090101

• Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma.

  Clinical drug investigation 20090101

• A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.

  Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg 20090101

• How can second-line therapy for metastatic renal cell carcinoma help to define an overall management strategy?

  Oncology 20090101

• Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib.

  Urologia internationalis 20090101

• Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20090101

• Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.

  Drug safety 20090101

• Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.

  Cancer journal (Sudbury, Mass.) 20090101

• 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma.

  Tumori 20090101

• [Treatment of extensive disease].

  Wiener medizinische Wochenschrift (1946) 20090101

• [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20090101

• New therapeutic approaches in the management of metastatic renal cell carcinoma.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20090101

• Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

  Journal of gastrointestinal cancer 20090101

• Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20090101

• Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.

  Oncology 20090101

• Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib.

  Urologia internationalis 20090101

• [Effect of sutent and celecoxib on the properties of endothelial cells in vitro].

  Voprosy onkologii 20090101

• Gastrointestinal stromal tumor: a bridge between bench and bedside.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20090101

• Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081215

• Cost effectiveness of sunitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081210

• Sunitinib malate as the salvage therapy in advanced rectal carcinoid tumor.

  International journal of colorectal disease 20081201

• Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.

  European urology 20081201

• Exploring the role of novel agents in the treatment of renal cell carcinoma.

  Cancer treatment reviews 20081201

• Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib.

  Molecular pharmacology 20081201

• Vascular complications of selected cancer therapies.

  Nature clinical practice. Cardiovascular medicine 20081201

• Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors.

  Toxicologic pathology 20081201

• Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib.

  Current gastroenterology reports 20081201

• [Vascular and renal effects of anti-angiogenic therapy].

  Nephrologie & therapeutique 20081201

• Imatinib-induced interstitial lung disease and sunitinib-associated intra-tumour haemorrhage.

  Hong Kong medical journal = Xianggang yi xue za zhi 20081201

• Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20081201

• Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib.

  European journal of medical research 20081124

• Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081120

• Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081120

• Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081110

• Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081110

• Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.

  Cancer letters 20081108

• Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib.

  British journal of cancer 20081104

• Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20081101

• Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.

  Toxicological sciences : an official journal of the Society of Toxicology 20081101

• Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone.

  European journal of cancer (Oxford, England : 1990) 20081101

• Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20081101

• [Molecular basis of targeted therapy in metastatic renal cancer].

  Der Pathologe 20081101

• Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase.

  Experimental biology and medicine (Maywood, N.J.) 20081101

• Documentation of thyroid function in clinical studies with sunitinib: why does it matter?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081101

• Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.

  Nature chemical biology 20081101

• Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma.

  Expert review of anticancer therapy 20081101

• Systemic therapy for metastatic renal cell carcinoma.

  The Urologic clinics of North America 20081101

• Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition.

  Archives of dermatology 20081101

• Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment.

  World journal of gastroenterology 20081021

• Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081015

• Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081015

• Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

  Clinical endocrinology 20081001

• Re: Pierre I. Karakiewicz, Nazareno Suardi, Claudio Jeldres, et al. Neoadjuvant Sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008;53:845-8.

  European urology 20081001

• Acute severe hypothyroidism induced by sunitinib.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20081001

• [Value of targeted therapies for renal cell cancer].

  Der Urologe. Ausg. A 20081001

• [Targeted therapy - point blank or single shot].

  Der Urologe. Ausg. A 20081001

• Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.

  Cancer 20081001

• Novel drugs for renal cell carcinoma.

  Expert opinion on investigational drugs 20081001

• [Systemic therapy of metastasizing renal cell carcinoma].

  Der Urologe. Ausg. A 20081001

• Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.

  European journal of cancer (Oxford, England : 1990) 20081001

• Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.

  The oncologist 20081001

• Rapid improvement in pain and functional level in a patient with metastatic renal cell carcinoma: a case report and review of the literature.

  Journal of palliative medicine 20081001

• Drug essentials. Small molecule multitargeted TKI therapy.

  Oncology (Williston Park, N.Y.) 20081001

• Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.

  Cancer 20080915

• Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080915

• Major treatment improvements encourage kidney cancer researchers to seek further gains.

  Journal of the National Cancer Institute 20080903

• Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy?

  European urology 20080901

• Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib.

  The Journal of surgical research 20080901

• Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.

  BJU international 20080901

• Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080901

• Sunitinib in the treatment of tubulocystic carcinoma of the kidney. A case report.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080901

• Heterogeneity of kinase inhibitor resistance mechanisms in GIST.

  The Journal of pathology 20080901

• von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

  The Journal of urology 20080901

• Targeted therapy in renal cell carcinoma.

  Current opinion in urology 20080901

• The case / progressive hypertension and proteinuria on anti-angiogenic therapy.

  Kidney international 20080901

• Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

  The oncologist 20080901

• Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update.

  Reviews on recent clinical trials 20080901

• Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer.

  Onkologie 20080901

• Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma.

  Onkologie 20080901

• [Renal cell carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080901

• Sunitinib-induced acute hemolysis without hypertension: a case report.

  Clinical genitourinary cancer 20080901

• Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.

  Clinical genitourinary cancer 20080901

• Cardiovascular toxicity of new agents.

  Clinical advances in hematology & oncology : H&O 20080901

• [Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].

  Bulletin du cancer 20080901

• Scrotal cutaneous side effects of sunitinib.

  The New England journal of medicine 20080828

• Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080820

• Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080820

• Watchdog set to reject four drugs for kidney cancer on the NHS.

  BMJ (Clinical research ed.) 20080814

• The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.

  British journal of cancer 20080805

• Sunitinib in the management of gastrointestinal stromal tumours (GISTs).

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20080801

• Sunitinib-related fulminant hepatic failure: case report and review of the literature.

  Pharmacotherapy 20080801

• Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080801

• Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080801

• Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease.

  Archives of dermatology 20080801

• [Molecular targeted therapy for renal cell carcinoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20080801

• Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.

  British journal of cancer 20080722

• Activity of sunitinib in patients with advanced neuroendocrine tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080710

• Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080710

• Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.

  Pediatric blood & cancer 20080701

• Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.

  The Journal of urology 20080701

• Pyoderma gangrenosum: another cutaneous side-effect of sunitinib?

  The British journal of dermatology 20080701

• SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation.

  International journal of radiation oncology, biology, physics 20080701

• Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?

  Nature clinical practice. Oncology 20080701

• Stability of sunitinib in oral suspension.

  The Annals of pharmacotherapy 20080701

• Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications.

  Oncology nursing forum 20080701

• Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies.

  Thyroid : official journal of the American Thyroid Association 20080701

• [Antiangiogenics: new therapeutic standards in metastatic kidney cancer].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20080701

• Novel approaches to imatinib- and sunitinib-resistant GIST.

  Current oncology reports 20080701

• [Gastrointestinal stromal tumors. An update].

  Revista medica de Chile 20080701

• Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.

  Blood 20080615

• A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours.

  British journal of cancer 20080603

• Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.

  Leukemia research 20080601

• Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit.

  Journal of cancer research and clinical oncology 20080601

• Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20080601

• Sunitinib therapy in renal cell carcinoma.

  BJU international 20080601

• Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor.

  Cancer 20080601

• Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.

  Anti-cancer drugs 20080601

• Targeted therapy in advanced non-small-cell lung cancer.

  Seminars in respiratory and critical care medicine 20080601

• Management of gastrointestinal stromal tumors.

  The Surgical clinics of North America 20080601

• The current status and evolving role of sunitinib in non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080601

• Developments in targeted therapy of advanced gastrointestinal stromal tumors.

  Recent patents on anti-cancer drug discovery 20080601

• Molecularly targeted therapy in breast cancer: the new generation.

  Recent patents on anti-cancer drug discovery 20080601

• Effect of sunitinib on growth and function of FRTL-5 thyroid cells.

  Thyroid : official journal of the American Thyroid Association 20080601

• Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.

  The New England journal of medicine 20080529

• [Lung cancer].

  Medizinische Klinik (Munich, Germany : 1983) 20080515

• Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.

  European urology 20080501

• Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?

  Journal of cancer research and clinical oncology 20080501

• Severe epistaxis with tyrosine kinase inhibitors.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20080501

• The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour.

  European journal of cancer (Oxford, England : 1990) 20080501

• Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.

  Bioorganic & medicinal chemistry letters 20080501

• Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.

  Molecular cancer therapeutics 20080501

• [GIST].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080501

• Sunitinib for treatment of advanced renal cell cancer: primary tumor response.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080415

• Cardiotoxicity associated with sunitinib.

  Lancet (London, England) 20080412

• Cardiotoxicity associated with sunitinib.

  Lancet (London, England) 20080412

• Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080410

• [Renal cell carcinoma and antiangiogenic therapies].

  Presse medicale (Paris, France : 1983) 20080401

• Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi.

  European urology 20080401

• Disillusionment bias in clinical trials testing new drugs.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20080401

• Remission of diabetes while on sunitinib treatment for renal cell carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080401

• Chemotherapeutic agents and the skin: An update.

  Journal of the American Academy of Dermatology 20080401

• Skin ulcers in Klippel-Trenaunay syndrome respond to sunitinib.

  Translational research : the journal of laboratory and clinical medicine 20080401

• Response to sunitinib in medullary thyroid cancer.

  Annals of internal medicine 20080401

• Treatment options for metastatic renal cell carcinoma: a review.

  The Canadian journal of urology 20080401

• [Neoadjuvant therapy for renal cancer].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20080401

• Severe gastrointestinal hemorrhage due to metastatic renal cell carcinoma to the pancreas successfully controlled by transarterial embolization and adjuvant administration of Sunitinib Malate.

  Hinyokika kiyo. Acta urologica Japonica 20080401

• Transient sunitinib-induced coma in a patient with fibromyxoid sarcoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080320

• A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.

  Cancer chemotherapy and pharmacology 20080301

• Acute cardiac failure after sunitinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080301

• Rare case of hemangiopericytoma responds to sunitinib.

  Translational research : the journal of laboratory and clinical medicine 20080301

• F-18 FDG PET/CT assessment of gastrointestinal stromal tumor response to sunitinib malate therapy.

  Clinical nuclear medicine 20080301

• Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080301

• [New drugs; sunitinib and sorafenib].

  Nederlands tijdschrift voor geneeskunde 20080223

• A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

  Journal of the National Cancer Institute 20080220

• [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].

  Nederlands tijdschrift voor geneeskunde 20080216

• Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib.

  Pediatric blood & cancer 20080201

• High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.

  European urology 20080201

• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.

  The Journal of steroid biochemistry and molecular biology 20080201

• New developments in multitargeted therapy for patients with solid tumours.

  Cancer treatment reviews 20080201

• Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080201

• [Cutaneous side effects of sorafenib and sunitinib].

  Annales de dermatologie et de venereologie 20080201

• Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.

  Clinical therapeutics 20080201

• New therapeutic options in gastrointestinal stromal tumors.

  Oncology (Williston Park, N.Y.) 20080201

• Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.

  Cancer 20080115

• Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080115

• Home blood-pressure monitoring in patients receiving sunitinib.

  The New England journal of medicine 20080103

• Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.

  Journal of cancer research and clinical oncology 20080101

• Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.

  Journal of neuro-oncology 20080101

• Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.

  The Journal of urology 20080101

• Molecular pathobiology of gastrointestinal stromal sarcomas.

  Annual review of pathology 20080101

• Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20080101

• Gentisyl alcohol derivatives from the marine-derived fungus Penicillium terrestre.

  Journal of natural products 20080101

• Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080101

• Brain metastases in patients with renal cell cancer receiving new targeted treatment.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080101

• Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080101

• Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080101

• A quantitative analysis of kinase inhibitor selectivity.

  Nature biotechnology 20080101

• Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis.

  Archives of dermatology 20080101

• [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].

  Bulletin du cancer 20080101

• Guillain-Barré syndrome after treatment with sunitinib malate?

  Oncology (Williston Park, N.Y.) 20080101

• [Molecular targeted therapy for renal cell carcinoma].

  Hinyokika kiyo. Acta urologica Japonica 20080101

• From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.

  Current medicinal chemistry 20080101

• [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].

  Annales de dermatologie et de venereologie 20080101

• [The role of angiogenesis in renal carcinoma].

  Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20080101

• Sunitinib-induced subungual splinter haemorrhage and acral erythema.

  European journal of dermatology : EJD 20080101

• Sarcomatoid differentiation of renal cell carcinoma: a clinical case with literature review.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20080101

• Posterior reversible encephalopathy syndrome during sunitinib therapy.

  Revue neurologique 20080101

• An update on the medical therapy of advanced metastatic renal cell carcinoma.

  Scandinavian journal of urology and nephrology 20080101

• Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy.

  PloS one 20080101

• [New therapeutic regimes in metastasic renal-cell carcinoma].

  Der Internist 20080101

• Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients.

  Oncology 20080101

• Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20080101

• Signaling inhibitors in metastatic renal cell carcinoma.

  Cancer journal (Sudbury, Mass.) 20080101

• The sex kitten of bioethics? Research ethics comes of age.

  The Hastings Center report 20080101

• Safety of nab-paclitaxel plus sunitinib: analysis of three cases.

  Anticancer research 20080101

• [ASCO 2008. Bevacizumab in advanced renal carcinoma].

  Tumori 20080101

• [Drug Interaction between Sutent (sunitinib) and Bi-spirogyl (spiramycin-metronidazol): risk of toxicity].

  Therapie 20080101

• [New drugs; sunitinib and sorafenib].

  Nederlands tijdschrift voor geneeskunde 20071229

• Targeted drugs for metastatic renal cell carcinoma.

  Lancet (London, England) 20071222

• A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

  Proceedings of the National Academy of Sciences of the United States of America 20071218

• Cardiac toxicity of sunitinib.

  Lancet (London, England) 20071215

• Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

  Lancet (London, England) 20071215

• Angiogenesis as targeted breast cancer therapy.

  Breast (Edinburgh, Scotland) 20071201

• Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats.

  Hepatology (Baltimore, Md.) 20071201

• Unanswered questions regarding the management of sunitinib-induced hypothyroidism.

  Nature clinical practice. Oncology 20071201

• Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib.

  International journal of urology : official journal of the Japanese Urological Association 20071201

• Allergic interstitial nephritis possibly related to sunitinib use.

  The American journal of geriatric pharmacotherapy 20071201

• Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.

  Clinical and experimental medicine 20071201

• Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.

  Clinical genitourinary cancer 20071201

• Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design.

  Clinical genitourinary cancer 20071201

• FLT3 kinase inhibitors in the management of acute myeloid leukemia.

  Clinical lymphoma & myeloma 20071201

• Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.

  Clinical research in cardiology : official journal of the German Cardiac Society 20071101

• Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report.

  Thyroid : official journal of the American Thyroid Association 20071101

• Sunitinib efficacy against advanced renal cell carcinoma.

  The Journal of urology 20071101

• Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.

  BioEssays : news and reviews in molecular, cellular and developmental biology 20071101

• Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20071101

• [Consensus on the medical treatment of gastrointestinal stromal tumors].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20071101

• Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071020

• Potential biomarkers in metastatic gastrointestinal stromal tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071015

• Tyrosine kinase inhibitors for chronic myelogenous leukemia.

  The New England journal of medicine 20071011

• Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.

  Neuro-oncology 20071001

• [Sunitinib and hypothyroidism].

  Annales d'endocrinologie 20071001

• Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.

  Experimental hematology 20071001

• Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.

  Annals of oncology : official journal of the European Society for Medical Oncology 20071001

• Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20071001

• Managing side effects of angiogenesis inhibitors in renal cell carcinoma.

  Onkologie 20071001

• Sunitinib.

  Expert opinion on pharmacotherapy 20071001

• [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].

  Bulletin du cancer 20071001

• New therapies in renal cell carcinoma.

  Current opinion in supportive and palliative care 20071001

• Macrocytosis due to treatment with sunitinib.

  The New England journal of medicine 20070927

• Temsirolimus for advanced renal-cell carcinoma.

  The New England journal of medicine 20070906

• Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10.

  European urology 20070901

• A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.

  The Journal of clinical endocrinology and metabolism 20070901

• Molecular basis for sunitinib efficacy and future clinical development.

  Nature reviews. Drug discovery 20070901

• Eccrine squamous syringometaplasia associated with sunitinib therapy.

  Journal of the European Academy of Dermatology and Venereology : JEADV 20070901

• Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070901

• Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070901

• Advances in the treatment of gastrointestinal stromal tumours.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070901

• Treatment options in renal cell carcinoma: past, present and future.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070901

• A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070901

• Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070901

• Sunitinib, sorafenib and mTOR inhibitors in renal cancer.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20070901

• [Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20070901

• Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070810

• Reversible posterior leukoencephalopathy syndrome induced by sunitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070810

• Sunitinib malate.

  Cancer chemotherapy and pharmacology 20070801

• Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

  Cancer 20070801

• Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.

  Pharmacotherapy 20070801

• American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.

  IDrugs : the investigational drugs journal 20070801

• [Imatinib . Sunitinib].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070801

• Second line therapies for the treatment of gastrointestinal stromal tumor.

  Current opinion in oncology 20070701

• Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.

  Current oncology reports 20070701

• Sunitinib malate and multiple receptor tyrosine kinases inhibitors: are they also novel drugs for chronic and neurophatic pain?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070701

• CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070701

• NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

  Journal of the National Comprehensive Cancer Network : JNCCN 20070701

• New challenges in kidney cancer therapy: sunitinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070701

• [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].

  Aktuelle Urologie 20070701

• Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy.

  Urology 20070701

• Complete cerebral response with sunitinib for metastatic renal cell carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070701

• Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.

  Clinical therapeutics 20070701

• [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].

  Zhonghua bing li xue za zhi = Chinese journal of pathology 20070701

• [Oral drugs inhibiting the VEGF pathway].

  Bulletin du cancer 20070701

• [Angiogenesis and renal cell carcinoma].

  Bulletin du cancer 20070701

• [Cutaneous side effects of antiangiogenic agents].

  Bulletin du cancer 20070701

• Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

  Journal of the National Cancer Institute 20070620

• Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

  Journal of the National Cancer Institute 20070620

• Mechanisms of adverse effects of anti-VEGF therapy for cancer.

  British journal of cancer 20070618

• Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.

  Lancet (London, England) 20070609

• Sunitinib relieves renal cell carcinoma spinal cord compression.

  European urology 20070601

• ASCO 2006 highlights: targeted therapy for renal cell carcinoma.

  Cancer treatment reviews 20070601

• [Anti-angiogenetic agents for solid tumors].

  La Revue de medecine interne 20070601

• Hypertension as a predictive factor of Sunitinib activity.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070601

• Sunitinib: bridging present and future cancer treatment.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070601

• Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.

  The oncologist 20070601

• Macrocytosis and cobalamin deficiency in patients treated with sunitinib.

  The New England journal of medicine 20070531

• Gastrointestinal stromal tumour.

  Lancet (London, England) 20070519

• [Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer].

  Nederlands tijdschrift voor geneeskunde 20070519

• Effect of sunitinib on metastatic gastrointestinal stromal tumor in patients with neurofibromatosis type 1: a case report.

  World journal of gastroenterology 20070514

• Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.

  Biochemical and biophysical research communications 20070504

• 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.

  Journal of medicinal chemistry 20070503

• [Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].

  Praxis 20070502

• Recent advances in therapy for gastrointestinal stromal tumors.

  Current oncology reports 20070501

• [Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot].

  Der Urologe. Ausg. A 20070501

• The role of KIT in the management of patients with gastrointestinal stromal tumors.

  Human pathology 20070501

• Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.

  BJU international 20070501

• Combination of target agents: challenges and opportunities.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070501

• Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.

  Nature reviews. Cancer 20070501

• Angiogenesis in cancer: molecular mechanisms, clinical impact.

  Langenbeck's archives of surgery 20070501

• Do the results of the new trials change the standard treatment of metastatic renal cell cancer?

  Onkologie 20070501

• Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib.

  Pharmacotherapy 20070501

• Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070501

• Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.

  Reviews on recent clinical trials 20070501

• Sunitinib and hypothyroidism.

  The New England journal of medicine 20070412

• Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity.

  Thyroid : official journal of the American Thyroid Association 20070401

• Design of clinical trials of radiation combined with antiangiogenic therapy.

  The oncologist 20070401

• Pharmacologic application of sunitinib malate in the management of gastrointestinal stromal tumors.

  Clinical journal of oncology nursing 20070401

• The effect of recent drug approvals on translational research and drug development.

  Clinical advances in hematology & oncology : H&O 20070401

• SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis.

  Translational research : the journal of laboratory and clinical medicine 20070301

• Sunitinib: from rational design to clinical efficacy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070301

• Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070301

• Emerging drugs for the treatment of soft tissue sarcomas.

  Expert opinion on emerging drugs 20070301

• Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20070301

• Two new drugs for renal cell carcinoma.

  The Medical letter on drugs and therapeutics 20070226

• Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070215

• KIT mutations in GIST.

  Current opinion in genetics & development 20070201

• New drugs 07, part I.

  Nursing 20070201

• Fatigue with sunitinib-induced hypothyroidism.

  The Lancet. Oncology 20070201

• Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.

  The oncologist 20070201

• Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.

  Current treatment options in oncology 20070201

• Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070115

• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  The New England journal of medicine 20070111

• Salvation by registration.

  The New England journal of medicine 20070111

• Renal-cell carcinoma--molecular pathways and therapies.

  The New England journal of medicine 20070111

• Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

  Journal of the National Cancer Institute 20070103

• Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

  The oncologist 20070101

• Newly approved therapies for RCC and their effect on the standard of care.

  Clinical advances in hematology & oncology : H&O 20070101

• Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects.

  Medical hypotheses 20070101

• PDGF receptors as targets in tumor treatment.

  Advances in cancer research 20070101

• Rationale and clinical results of multi-target treatments in oncology.

  The International journal of biological markers 20070101

• Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.

  Journal of translational medicine 20070101

• C-kit, GIST, and imatinib.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20070101

• The role of targeted therapy in metastatic renal cell carcinoma.

  TheScientificWorldJournal 20070101

• [Effect of angiogenesis inhibitors on renal cell carcinoma].

  Magyar onkologia 20070101

• Targeted therapies for kidney cancer in urologic practice.

  Urologic oncology 20070101

• [Angiogenesis targeting in renal carcinomas].

  Bulletin du cancer 20070101

• [News on ASCO 2007. Sunitinib in the treatment of metastatic renal carcinoma and gastrointestinal stromal tumors].

  Tumori 20070101

• Brain metastasis in renal cell cancer responding to sunitinib.

  Anticancer research 20070101

• [New treatments for renal carcinoma].

  Anales del sistema sanitario de Navarra 20070101

• Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061220

• Targeting von Hippel-Lindau pathway in renal cell carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061215

• Targeted therapy for metastatic renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061210

• ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib.

  Cancer science 20061201

• Treatment outcome for metastatic papillary renal cell carcinoma patients.

  Cancer 20061201

• New weapons to snuff out kidney cancer.

  Nursing 20061201

• Molecularly targeted therapy in renal cell carcinoma: where do we go from here?

  Expert review of anticancer therapy 20061201

• Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.

  Expert review of anticancer therapy 20061201

• Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases.

  Clinical genitourinary cancer 20061201

• Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects.

  Clinical genitourinary cancer 20061201

• Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma.

  Clinical genitourinary cancer 20061201

• Toxicities of antiangiogenic therapy in non-small-cell lung cancer.

  Clinical lung cancer 20061201

• Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.

  Annals of internal medicine 20061107

• Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

  Annals of internal medicine 20061107

• Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine.

  Annals of oncology : official journal of the European Society for Medical Oncology 20061101

• FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).

  Leukemia 20061101

• Gastrointestinal stromal tumors: imatinib and beyond.

  Current treatment options in oncology 20061101

• Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.

  Clinical colorectal cancer 20061101

• The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061015

• Sunitinib for imatinib-resistant GIST.

  Lancet (London, England) 20061014

• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

  Lancet (London, England) 20061014

• Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

  BJU international 20061001

• An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

  The Journal of clinical endocrinology and metabolism 20061001

• [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].

  Der Urologe. Ausg. A 20061001

• The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling.

  Molecular cancer therapeutics 20061001

• [Sunitinib for gastrointestinal stromal cell tumors and advanced renal cell carcinoma].

  Medizinische Monatsschrift fur Pharmazeuten 20061001

• Molecular biology of renal cell carcinoma.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20061001

• The role of angiogenesis inhibition in the treatment of breast cancer.

  Clinical advances in hematology & oncology : H&O 20061001

• Three new drugs available to fight kidney cancer.

  Journal of the National Cancer Institute 20060906

• New treatment approaches in metastatic renal cell carcinoma.

  Current opinion in urology 20060901

• Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling.

  Cancer science 20060901

• Long-term response with sunitinib for metastatic renal cell carcinoma.

  Urology 20060901

• Pharmacy benefit spending on oral chemotherapy drugs.

  Journal of managed care pharmacy : JMCP 20060901

• We have a new treatment, but you can't afford it.

  Journal of the National Comprehensive Cancer Network : JNCCN 20060901

• Good news for metastatic renal cell cancer.

  Health news (Waltham, Mass.) 20060901

• A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20060801

• New hope for RCC patients.

  European journal of cancer (Oxford, England : 1990) 20060801

• Current and future management of GIST.

  Clinical advances in hematology & oncology : H&O 20060801

• Trials probe new agents for kidney cancer.

  JAMA 20060712

• Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour.

  European journal of gastroenterology & hepatology 20060701

• Sunitinib in patients with metastatic renal cell carcinoma.

  JAMA 20060607

• A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage.

  JAMA 20060607

• [Molecular-targeted agents in breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.

  Drugs of today (Barcelona, Spain : 1998) 20060601

• Molecular targeting therapy for renal cell carcinoma.

  International journal of clinical oncology 20060601

• Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma.

  Clinical genitourinary cancer 20060601

• Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.

  Clinical genitourinary cancer 20060601

• New therapeutic options for renal cell carcinoma.

  Clinical advances in hematology & oncology : H&O 20060601

• Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060520

• Sunitinib malate for the treatment of solid tumours: a review of current clinical data.

  Expert opinion on investigational drugs 20060501

• Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.

  Molecular cancer therapeutics 20060501

• Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060415

• New drug increases survival in stomach cancer.

  The Lancet. Oncology 20060401

• Sunitinib maleate.

  Nature reviews. Drug discovery 20060401

• [Molecular targets in colon cancer].

  Therapeutische Umschau. Revue therapeutique 20060401

• Targeted therapy for metastatic renal cell carcinoma.

  British journal of cancer 20060313

• [Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway].

  Der Urologe. Ausg. A 20060301

• VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.

  Current oncology reports 20060301

• Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects.

  Anti-cancer drugs 20060301

• Multi-target inhibitors in non-small cell lung cancer (NSCLC).

  Annals of oncology : official journal of the European Society for Medical Oncology 20060301

• Assessment of anti-metastatic drug efficacy via localization and quantification of ex vivo murine bone tumor load using high-throughput MRI T1 parametric analysis.

  NMR in biomedicine 20060201

• [Progress in therapeutic strategy for renal cell carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060201

• New targets, therapies, and toxicities: lessons to be learned.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060101

• Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060101

• Treatment options in metastatic renal carcinoma: an embarrassment of riches.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060101

• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060101

• Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy.

  International journal of radiation oncology, biology, physics 20060101

• New targeted therapy for rare stomach, kidney cancers.

  FDA consumer 20060101

• Renal cell carcinoma: today's targeted therapies improving tomorrow's outcomes.

  ONS news 20060101

• Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.

  ONS news 20060101

• New drugs: rasagiline mesylate, conivaptan hydrochloride, and sunitinib malate.

  Journal of the American Pharmacists Association : JAPhA 20060101

• Sunitinib.

  Drugs 20060101

• Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.

  Reviews on recent clinical trials 20060101

• SU11248 and AG013736: current data and future trials in renal cell carcinoma.

  Clinical genitourinary cancer 20051201

• Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase.

  Bioorganic & medicinal chemistry letters 20051001

• Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.

  Journal of medicinal chemistry 20050922

• Promising systemic therapy for renal cell carcinoma.

  Current treatment options in oncology 20050901

• Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.

  Clinical lung cancer 20050901

• Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?

  Annals of internal medicine 20050816

• Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050815

• Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.

  BJU international 20050801

• Sonographic depiction of changes of tumor vascularity in response to various therapies.

  Ultrasound quarterly 20050601

• Multi-kinase inhibitors create buzz at ASCO.

  Nature biotechnology 20050601

• A small molecule-kinase interaction map for clinical kinase inhibitors.

  Nature biotechnology 20050301

• Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.

  Current oncology reports 20050301

• [Possibility of targeting FLT3 kinase for the treatment of leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20050301

• A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050210

• A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

  Blood 20050201

• Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.

  Blood 20041215

• Su-11248 Sugen.

  Current opinion in investigational drugs (London, England : 2000) 20041201

• Novel agents for the treatment of advanced kidney cancer.

  Clinical advances in hematology & oncology : H&O 20041001

• Three molecularly targeted drugs tested in kidney cancer clinical trials.

  Journal of the National Cancer Institute 20040901

• Early clinical data with small-molecule vascular endothelial growth factor tyrosine kinase receptor inhibitors.

  Clinical lung cancer 20040901

• New cancer therapeutics: target-specific in, cytotoxics out?

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20040401

• Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20040401

• Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor.

  Oncogene 20040226

• Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction.

  Journal of chromatography. A 20040123

• Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials.

  Drug development and industrial pharmacy 20040101

• The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels.

  Angiogenesis 20040101

• New therapeutic strategies for soft tissue sarcomas.

  Current treatment options in oncology 20031201

• An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031115

• Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.

  The Journal of pharmacology and experimental therapeutics 20031101

• [Current screening for molecular target therapy of cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031101

• Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with 'standard of care' therapeutic agents for the treatment of breast cancer.

  Molecular cancer therapeutics 20031001

• A widely applicable, high-throughput TR-FRET assay for the measurement of kinase autophosphorylation: VEGFR-2 as a prototype.

  Journal of biomolecular screening 20030801

• SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.

  Cancer research 20030715

• SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

  Blood 20030501

• SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

  Molecular cancer therapeutics 20030501

• Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.

  Journal of medicinal chemistry 20030327

• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030101

• SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.

  Clinical & experimental metastasis 20030101

• Intestinal absorption of amino acids in rats infected with Nematospiroides dubius.

  Comparative biochemistry and physiology. A, Comparative physiology 19751201